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ABSTRACT
Freeman, Amanda Noelle Ph.D., Biomedical Sciences Ph.D. Program, Wright State
University, 2013. Differential Regulation of the Hippocampal Taurine Transporter
Protein in Rat Brain: Mechanisms Contributing to Neuronal Volume Regulation.

Background. In osmotic edema, net efflux of taurine from neurons and
accumulation by astrocytes contributes to neuronal volume regulation and astrocytic
swelling. Taurine is accumulated in both cell types by a sodium- and chloride-dependent
72-75 kDa protein transporter, TauT. TauT functional activity decreases in osmotically
swollen neurons but is unaltered in swollen astrocytes, in vitro. This swelling-induced
downregulation of neuronal TauT activity is blocked with the tyrosine kinase (TK)
inhibitor, genistein. In contrast, PKC activation has no effect on neuronal TauT, but
inhibits astrocytic TauT. Thus, we hypothesize that during osmotic swelling, neuronal
TauT activity is regulated by a TK signaling pathway whereas astroglial TauT activity is
regulated by serine/threonine kinases. This differential regulation contributes to neuronal
volume regulation and astrocytic swelling via taurine redistribution during osmotic brain
edema. Methods. Primary neuronal and astrocytic cultures from rat hippocampus were
incubated under iso- or hypo-osmotic conditions in the presence or absence of activators
or inhibitors of TK or PKC. Subcellular TauT localization was measured after 30 min
using cell fractionation, cell surface biotinylation, and western blot analyses.
Phosphorylation was measured after 30 min using immunoprecipitation and western blot
analyses with phosphoprotein-specific antibodies. Results. We found neuronal and
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astroglial TauT primarily localized to cytosolic and membrane/particulate fractions in
isoosmotic conditions. However, cell surface biotinylation of TauT decreased in swollen
neurons while phosphorylation of tyrosine residues increased. In contrast,
phosphorylation of serine and threonine on neuronal TauT was unchanged. Surface
biotinylation decreased and phosphorylation of serine and threonine residues on
astrocytic TauT increased upon treatment with 1 µM PMA. Cell surface biotinylation and
phosphorylation of TauT in astrocytes were unaffected by cell swelling. Conclusions.
The results suggest the signal for neuronal TauT translocation from the cell membrane
during hypoosmotic cell swelling involves tyrosine phosphorylation. Membrane
localization of astroglial TauT remains unchanged during hypoosmotic cell swelling.
These changes may account for the observed reduction in functional TauT activity in
swollen neurons and may contribute to neuronal volume regulation during osmotic
edema.
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I. INTRODUCTION
Edema, a condition of increased fluid content in the brain, may occur in patients
presenting with a variety of pathological conditions including traumatic brain injury
(TBI), stroke, cardiac arrest, and metabolic encephalopathies (e.g. hepatic
encephalopathy) (Franco, Panayiotidis et al. 2008). Since cell function depends on the
homeostatic maintenance of intracellular and extracellular ion concentrations, increased
fluid content during brain edema can have profound effects on brain function and neuron
viability and can directly alter mental status (Fisher, Cheema et al. 2008; Franco,
Panayiotidis et al. 2008). The alteration of ion gradients leads to increased seizure
susceptibility while second messenger molecules become diluted thus impairing cell
signaling cascades. More generally, an increase in total brain volume compromises the
spatial relationships between CNS cells (e.g. neurons and astrocytes) and the extracellular
space (Fisher, Cheema et al. 2008). Small increases in volume can increase neuronal
excitability, prevent oxygen and nutrients from reaching important brain structures, and
increase intracranial pressure enough to compress the brain stem onto the base of the
skull or cause it to herniate, leading to death due to cardiac or respiratory arrest (Fisher,
Cheema et al. 2008).
No effective clinical treatment is currently available to reverse the causes of
progressive brain swelling. Thus, brain edema and the resulting elevation in intracranial
pressure are treated only symptomatically (e.g. mannitol infusion, hyperventilation,
hypothermia, barbiturate coma, decompressive craniectomy)
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(Phillis, Song et al. 1999; Unterberg, Stover et al. 2004; Marmarou, Signoretti et al.
2006). Understanding the regulation of brain cell osmolyte contents and brain volume is
of particular interest as this will reveal more specific mechanisms of brain swelling and
illuminate how brain edema can be more effectively treated to prevent undesirable
outcomes.
Taurine, the second most abundant free amino acid in the brain, is a sulfur amino
acid which is involved in the regulation of brain cell volume (Nagelhus, Lehmann et al.
1993). Taurine is accumulated in both neurons and astrocytes by a specific sodium- and
chloride-dependent membrane transporter, TauT (Smith, Borden et al. 1992). The TauT
protein cloned from several sources has twelve membrane spanning regions and a
calculated molecular weight of 72-75 kDa with several potential sites for phosphorylation
on cytoplasmic loops and glycosylation on extracellular domains (Smith, Borden et al.
1992).
Neuronal and astrocytic forms of TauT are thought to be similar in structure;
however, considerable evidence suggests TauT is differentially regulated in neurons and
astrocytes. During osmotic brain edema, net efflux of taurine from neurons and
accumulation by astrocytes contributes to neuronal volume regulation and concomitant
astrocytic swelling (Nagelhus, Lehmann et al. 1993). In accordance with this, TauT
functional activity decreases in osmotically swollen neurons but is not altered in swollen
astrocytes in vitro. Inhibition of tyrosine kinases blocks the decrease in TauT functional
activity in swollen neurons (Olson and Martinho 2006a; Olson and Martinho 2006b). In
contrast, activation of PKC has no effect on neuronal TauT activity, but inhibits the
transporter in astrocytes (Jones, Miller et al. 1991; Beetsch and Olson 1996; Olson and
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Martinho 2006a; Olson and Martinho 2006b). Thus, our overall hypothesis posits that the
neuronal taurine transporter protein is regulated by a tyrosine kinase signaling pathway
whereas the astroglial taurine transporter is regulated by serine/threonine kinases. This
differential regulation contributes to neuronal volume regulation and astroglial swelling
during osmotic brain edema, which in part accounts for cytotoxic edema. In this study,
focus is placed on post-translational modifications and changes in subcellular localization
of TauT in neurons and astrocytes in response to hypoosmotic cell swelling. Study of
cell-specific intracellular signaling pathways that regulate TauT activity enhance our
understanding of the adaptive response of the brain to edema and open a new avenue of
research into potential targets for treatment of this common condition of brain pathology.
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II. REVIEW OF THE LITERATURE
Brain Edema and Resulting Pathologies
Regulation of cellular volume is critical for maintaining proper cell and organ
function. An increase in cellular fluid content increases cell volume and changes the
homeostatic balance of intracellular and extracellular ion concentrations. In the brain this
results in increased seizure susceptibility, decreased neuron viability, and direct alteration
of mental status (Arundine, Aarts et al. 2004; Azouvi, Vallat-Azouvi et al. 2009). While
brain edema has been described in various ways, there is general acceptance for
distinguishing two major types of brain edema, vasogenic and cytotoxic (Klatzo 1987).
Vasogenic edema is an accumulation of extracellular fluid usually resulting from
a disruption of the blood brain barrier (BBB) (Lu, Wu et al. 2006). Cytotoxic edema is an
increase in intracellular fluid induced by disruption of ionic homeostasis and thus the
osmotic equilibrium of cells (Lu, Wu et al. 2006). Cytotoxic brain edema predominates in
various pathologies including traumatic brain injury (TBI), stroke, diabetic ketoacidosis,
hepatic encephalopathy, Reye’s syndrome, and cardiac arrest (Franco, Panayiotidis et al.
2008).
Cytotoxic edema is a major finding in Reye’s syndrome. Usually associated with
the use of aspirin during a viral illness, the syndrome is characterized by acute noninflammatory encephalopathy combined with fatty vacuolization of hepatocytes (Weiner,
Bachur et al. 1994-2013). While the pathogenesis of Reye’s syndrome remains unclear, it
is postulated that hyperammonemia produced due to injury of hepatic cellular
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mitochondria ultimately causes edema of astrocytes (Weiner, Bachur et al. 1994-2013).
The resulting cerebral edema and increased intracranial pressure is the leading cause of
death for patients with Reye’s syndrome and survivors are at increased risk for long-term
neurological sequelae (Weiner, Bachur et al. 1994-2013).
Cytotoxic edema is also a devastating consequence of diabetic ketoacidosis
(DKA), especially in children (Jeha and Haymond 2013). It is believed that cases of
cerebral edema following DKA develop because of overly rapid correction of a
previously hypertonic state (Jeha and Haymond 2013). In other words the increased
glucose and ketones present during DKA cause a preferential loss of water from
intracellular compartments. Later, the brain generates osmolytes which draw water back
into the cerebrum and thus correct intracellular dehydration. This leaves the brain
hyperosmotic relative to normal plasma osmolarity so that too rapid restoration of DKA
with the use of hypotonic fluids renders the brain susceptible to swelling (Jeha and
Haymond 2013).
Cytotoxic edema is also a pathological manifestation of traumatic brain injury, a
major cause of morbidity and mortality in both industrialized nations and developing
countries (Park, Bell et al. 2008). TBI results in over 275,000 hospitalizations and
contributes to nearly one-third of all injury-related deaths each year in the United States
(Geddes and Cargill 2001). It results from motor vehicle accidents, firearms, falls,
assault, sports-related concussions, child abuse, etc (Madikians and Giza 2006). In
particular, TBI is prevalent in combat areas where civilian and military personnel are
subjected to the use of explosive devices (Park, Bell et al. 2008). Mechanical deformation
of brain tissue initiates a cascade of cellular events that ultimately leads to neuronal cell
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injury or death (Geddes and Cargill 2001). Primary injury which directly damages
neurons, blood vessels, and glia is amplified by secondary injuries including hypoxia,
ischemia, and edema (Lu, Wu et al. 2006). The long term morbidities from TBI are
devastating and include impairment of sensation, movement, cognition, language, and
emotion (Faul, Xu et al. 2010). Several studies have revealed that the major component
of brain swelling following TBI results from cytotoxic edema rather than vasogenic
edema (Marmarou, Fatouros et al. 2000; Unterberg, Stover et al. 2004). In a study by
Marmarou, increases in brain tissue water (i.e. cytotoxic edema) accounted for 82% of
increased brain volume after TBI, whereas vascular engorgement (i.e. vasogenic edema)
accounted for only 18% of increased brain volume (Marmarou, Fatouros et al. 2000).
Apparent diffusion coefficient (ADC)1 values were also reduced in patients with
significant brain swelling consistent with a cytotoxic process (Marmarou, Signoretti et al.
2006; Pasco, Ter Minassian et al. 2006). The BBB remained intact in the swollen brain
and cerebral blood volume was decreased below normal in head injured patients further
suggesting that cytotoxic edema was the major process in brain swelling (Marmarou,
Fatouros et al. 2000).
While many authors report in the literature the presence of cytotoxic edema (as
described above), this classification is a misnomer. Strictly speaking, cytotoxic edema
implies that a cellular toxin is required to produce intracellular swelling (Betz, Iannotti et
al. 1989). Although this may be true in some cases, i.e. the high ammonia levels in
Reye’s syndrome leading to intracellular swelling, a cellular toxin is not necessary to
1

ADC values are taken from non-invasive quantitative diffusion MRI which is used to document
intracellular vs. extracellular edema. While ADC values are useful in distinguishing types of edema, one
must be careful to interpret results because many factors restrict water diffusion including disrupted energy
metabolism and ion homeostasis (which decreases the extracellular space via cell swelling), increased
tortuosity of extra- and intracellular spaces, and increased intracellular viscosity.
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produce intracellular swelling. In many cases intracellular swelling is simply the result of
a change in the osmotic balance between cells and their external environment. Osmotic
edema which may be a component of a cytotoxic process may be the more appropriate
term for many of these processes. Therefore, despite the use of the term ‘cytotoxic’ in the
literature, I will report ‘osmotic’ edema in the remainder of this document.
Since brain function (e.g. metabolism, cell proliferation, etc.) depends on the
homeostatic maintenance of intracellular and extracellular ion concentrations, the
increased fluid content during brain edema can directly alter mental status (Fisher,
Cheema et al. 2008; Franco, Panayiotidis et al. 2008). As the brain swells, intracranial
pressure (ICP) increases and brain expansion compromises spatial relationships between
central nervous system (CNS) cells that are important for neural function. Increased brain
volume also impairs cerebral perfusion and oxygenation and contributes to secondary
ischemic injuries (Unterberg, Stover et al. 2004). As ICP increases with brain swelling
the brain stem can potentially herniate through the foramen magnum causing death due to
cardiac or respiratory arrest (Fisher, Cheema et al. 2008). These untoward consequences
of brain edema make regulation of cell volume and brain water content essential for
preventing detrimental outcomes.
Currently, there is no effective clinical treatment available for progressive brain
swelling. For decades brain edema has been treated symptomatically by focusing on
decreasing ICP (e.g. mannitol infusion, hyperventilation, hypothermia, barbiturate coma)
(Phillis, Song et al. 1999; Unterberg, Stover et al. 2004; Marmarou, Signoretti et al.
2006). Since cellular osmoregulation underlies many disease states and their
complications, rapid correction of osmolar disturbances by pharmacological manipulation
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of osmolyte uptake and efflux is crucial in the treatment of these pathologies.
Understanding the regulation of electrolyte, osmolyte, and brain water content in cells of
the CNS is of particular interest for uncovering the mechanisms of brain swelling and
elucidating how brain edema may be more effectively treated to prevent secondary
undesirable outcomes.

Cell Volume Regulation
When cells are exposed to hypo- or hyper-osmotic conditions, the change in
extracellular solute concentration creates a transmembrane gradient which leads to water
flux across the plasma membrane (Chamberlin and Strange 1989). In osmotic edema seen
in cases of traumatic brain injury, extracellular K+ increases via leakage through damaged
ion channels especially in neurons. The increased extracellular K+ results in uptake of
KCl followed by water primarily in astrocytes to maintain the balance of electrolytes and
thus contributes to astrocytic cell swelling (Sahuquillo, Poca et al. 2001; Kimelberg
2004). In fact, microscopically, the edema appears to be primarily a result of astrocytic
swelling plus some swelling of neuronal dendrites with a decrease in the volume of the
extracellular space (Kimelberg 2004).
Under normal physiologic conditions, cells respond to volume changes by
activating volume regulatory mechanisms (e.g. membrane transport and metabolic
pathways) which alter intracellular solute concentrations to prevent excessive swelling or
shrinkage (Chamberlin and Strange 1989). Swollen cells decrease their volume by
regulatory volume decrease (RVD), whereas shrunken cells increase their volume by
regulatory volume increase (RVI) (Chamberlin and Strange 1989; McManus, Churchwell
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et al. 1995; Lang, Busch et al. 1998). Volume regulation involves the transport of both
inorganic ions (e.g. K+ and Cl-) and organic osmolytes (e.g. taurine, myo-inositol, and
betaine) followed osmotically by the gain or loss of water (Chamberlin and Strange 1989;
Trachtman 1991; McManus, Churchwell et al. 1995; Matskevitch, Wagner et al. 1999).
The majority of the initial change in cell osmolyte content following abrupt
changes in extracellular osmolality is accounted for by inorganic electrolytes which are
regulated by a balance between active ion pumps (e.g. Na+/K+-ATPase) and passive leak
pathways (Trachtman 1991; Hallows and Knauf 1994). In acute stages of osmotic stress,
cellular potassium and chloride contents are altered via transport by Na+/Cl- and Na+-K+2Cl- (NKCC) cotransporters, Na+/H+ and Cl-/HCO3 exchangers, and various ion channels
(Trachtman 1991). Loss of KCl usually accompanies RVD whereas uptake of KCl or
NaCl usually accompanies RVI (Chamberlin and Strange 1989; McManus, Churchwell et
al. 1995; Adragna, Di Fulvio et al. 2004). The loss of KCl during RVD is generally due
to transporters such as the K+/Cl- cotransporter (KCC) and separate K+ and Cl- channels
in mammalian cells (Hallows and Knauf 1994). Pasantes-Morales et al. described these
changes in ion contents of cultured cerebellar neurons following osmotic swelling. After
exposure to a large hypoosmotic challenge there was a rapid increase in cell volume,
followed by a gradual decrease back toward normal accomplished, in part, via efflux of
K+ and Cl- and also release of taurine from the cells (Pasantes-Morales, Franco et al.
2002). On the other hand, under conditions of cell shrinkage, Na+ and Cl- are initially
accumulated followed by secondary exchange of Na+ for K+ by the Na+/K+-ATPase
resulting in a net gain of KCl (Hallows and Knauf 1994). For example, in pig pulmonary
endothelial cells, influx of sodium and potassium via NKCC is the primary response to
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hypertonicity (i.e. cell shrinkage). The increase in sodium concentration intracellularly is
thought to increase Na+/K+-ATPase activity which then exchanges sodium for potassium
resulting in a net gain of potassium (Petronini, Alfieri et al. 2000).
Unfortunately, high intracellular concentrations of ions which may result from
RVI can be detrimental to cell function because these charged molecules interfere with
enzyme function and properties of other macromolecules (Lang, Busch et al. 1998;
Schliess and Haussinger 2002). Accumulation of inorganic ions causes variations in ionic
strength and perturbs catalytic rates, ligand binding properties, structural conformation
(destabilization of tertiary structure) and assembly of important enzymes (Yancey, Clark
et al. 1982; Somero 1986; Trachtman 1991). These effects are due partially to their
binding to active sites and partially to their ability to form complexes with free substrates
or cofactors (Somero 1986).
Cells are able to combat this problem by accumulating non-perturbing (a.k.a.
stabilizing/compatible) organic osmolytes (Trachtman 1991; McManus, Churchwell et al.
1995; Matskevitch, Wagner et al. 1999). Organic osmolytes are in high concentration in
the cytosol and are accumulated by energy-dependent transport or changes in the rates of
synthesis or degradation (Chamberlin and Strange 1989; McManus, Churchwell et al.
1995; Handler and Kwon 2001). The relative inertness of organic osmolytes and their
neutrality at physiological pH allow them to be accumulated without deleterious effects
on cell structure or function (Chamberlin and Strange 1989; Burg 1995; McManus,
Churchwell et al. 1995). Organic osmolytes are generally low molecular weight solutes,
either uncharged or zwitterionic. They do not interact strongly with substrates, cofactors,
or modulators (Somero 1986; Trachtman 1991). They are also unable to interact strongly
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with dissociating side chains of protein amino acids, lack interactions with ligand binding
sites thus conserving Km values, and are excluded from the water surfaces of proteins
which stabilizes protein structure (Yancey, Clark et al. 1982; Somero 1986; Trachtman
1991). Additionally organic osmolytes typically do not get incorporated into larger
structures (i.e. proteins) and remain free in the cytosol (Trachtman 1991).
The three major classes of organic osmolytes which are important in the brain are
polyols (e.g. sorbitol and myo-inositol), methylamines (e.g. betaine and
glycerylphosphorylcholine), and amino acids and their derivatives (e.g. taurine)
(McManus, Churchwell et al. 1995). Many of the organic osmolytes are taken up by
Na+/Cl--dependent transporters located in the plasma membrane of cells (Burg 1995;
McManus, Churchwell et al. 1995). The cellular response to volume perturbations
follows a biphasic pattern in which electrolyte content is altered in the early stages
followed by a later change in organic osmolyte content. Upon exposure to hypertonic
conditions, cells initially shrink but then respond with RVI by accumulating organic
osmolytes to maintain normal volume (Burg 1995). Exposure to hypotonic conditions, on
the other hand, causes cells to initially swell but then respond with RVD by extruding
organic osmolytes to maintain normal volume (Kimelberg 2005). Efflux of organic
osmolytes is mediated by non-selective swelling-activated membrane channels and by
downregulation of uptake mechanisms (McManus, Churchwell et al. 1995).
While much attention has been paid to the kinetic characteristics of organic
osmolyte transporters during cell volume regulation, the literature lacks studies regarding
the post-translational modifications of transporters and the signaling mechanisms that
may affect transport kinetics. Furthermore, studies that have attempted to look beyond
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transport kinetics often focus on rates of transcription of osmolyte transporters or of
enzymes responsible for organic osmolyte synthesis. However, they stop short of
assessing modifications that occur to transporters already present on the plasma
membrane. In addition, reports of kinetic data fail to correlate other forms of transporter
regulation, such as protein trafficking, that are known to commonly occur in a variety of
cells types. Thus, it is necessary to pursue molecular studies focused on post-translational
modifications and mechanisms of protein trafficking to complete the picture of osmolyte
transporter regulation following cell volume perturbations.

Organic Osmolyte Transporters in Brain Cells
In vitro, both astrocytes and neurons swell under conditions of hypoosmotic
stress, although astrocytes swell to a greater extent in vivo (Fisher, Cheema et al. 2008).
Astrocytes and neurons, like most cells, are able to respond to cell volume changes by
regulation of membrane transport processes including transporters which accumulate
intracellular osmolytes. In brain cells, as in other cell types, most organic osmolytes are
taken up via Na+/Cl--dependent transporters that use the Na+ electrochemical gradient
created and maintained by the Na+/K+-ATPase as the driving force for transport of
substrate (Clark and Amara 1993; Masson, Sagne et al. 1999). These Na+/Cl--dependent
transporters belong to the SLC6 transporter superfamily which is comprised of
transporters of monoamines, amino acid neurotransmitters, and other osmolytes and
substrates (Sitte, Farhan et al. 2004). The usual stoichiometry for transport is 2Na+:1Cl-:1
zwitterion although some transporters require other molecules (e.g. the serotonin
transporter also requires K+ antiport) (Clark and Amara 1993; Masson, Sagne et al.

12

1999). Dopamine, GABA, norepinephrine, serotonin, glycine, taurine, L-proline,
creatine, and betaine all have transporters encoded by genes that are members of this
superfamily (Masson, Sagne et al. 1999; Chen, Reith et al. 2004). The transporters have
been found in both neurons and astrocytes but also are present in non-neuronal tissues
(Chen, Reith et al. 2004).
SLC6 transporters have a high affinity for their substrate(s) and are saturable
(Chen, Reith et al. 2004). They typically are composed of twelve α-helical
transmembrane domains (TMD) (i.e. 12 stretches of 15-25 hydrophobic amino acids) and
have cytoplasmic N- and C-termini (Liu, Mandiyan et al. 1992; Masson, Sagne et al.
1999; Chen, Reith et al. 2004; Sitte, Farhan et al. 2004). The SLC6 transporters also have
large extracellular loops. The extracellular loop between TMD3 and TMD4 contains
potential sites for glycosylation which may be important for proper folding/conformation
of the protein, cell-cell adhesions, or trafficking in the cell (Liu, Mandiyan et al. 1992;
Clark and Amara 1993; Kilberg, Stevens et al. 1993; Chen, Reith et al. 2004).
Transmembrane domain 1 is speculated to form a pore loop structure with the potential
for recognition of substrate and is associated with the plasma membrane while the highly
homologous N-terminus (TMD1-TMD4) may be involved in Na+ and Cl- transport with
the TMD2 domain responsible for sodium recognition (Masson, Sagne et al. 1999). The
C-terminus (TMD7-TMD12) is more divergent than the N-terminus and may be involved
with substrate recognition and/or inhibitor binding (Masson, Sagne et al. 1999).

Cytoskeletal Regulation of Cell Volume
Actin filaments are the smallest components of the cytoskeleton, averaging 5-7
nm in width (Mills, Schwiebert et al. 1994). They are ubiquitous structural components of
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all eukaryotic cells and are composed of double-stranded, α-helical polymers of
monomeric G-actin (Mills, Schwiebert et al. 1994). The G-actin monomers are in a
constant state of flux, assembling and disassembling into F-actin filaments (Mills,
Schwiebert et al. 1994). While intact cells favor actin polymerization, a pool of G-actin
monomers, sequestered by profilin, is readily available allowing actin filaments to
polymerize or depolymerize in response to various stimuli (Mills, Schwiebert et al.
1994). Actin filaments often concentrate in the submembranous cell cortex and interact
with actin-binding proteins which attach to integral and peripheral membrane proteins
forming a membrane-cytoskeleton (Mills, Schwiebert et al. 1994).
Alterations in the organization of the actin cytoskeleton have been shown to
accompany volume changes in many cells (Cornet, Lambert et al. 1993). Ehrlich ascites
tumor cells demonstrate a net decrease in F-actin content and a decrease in actin
polymerization during hypoosmotic cell swelling. Reorganization of actin in these cells
occurs gradually with time and coincides with the time course of RVD (Cornet, Lambert
et al. 1993). Hyperosmotic cell shrinkage produces the opposite effect, a net increase in
F-actin content and actin polymerization (Hossmann 1989; Hubsman, Yudkovsky et al.
2001). In MDCK cells, drugs that disrupt the actin cytoskeleton augment normal
regulatory transport processes (De Matteis and Morrow 1998; Dalby 2003). Transporters
shown to be regulated directly by actin filaments include ENaC, CFTR, Cl- channels, and
K+ channels (Pedersen, Hoffmann et al. 2001). The cGMP-gated cation channel in rod
photoreceptors, the nACh receptor channel at the neuromuscular junction, the voltagedependent Na+ channel in neurons, and the Cl-/HCO3- exchanger in renal epithelia are
linked to F-actin via ankyrin and spectrin and these interactions are thought to regulate
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opening and closing of the ion channels (Mills, Schwiebert et al. 1994). It has been
suggested that actin filaments also may mediate vesicle insertion of membrane
transporters in response to volume perturbations (Pedersen, Hoffmann et al. 2001).
Therefore, it seems likely that F-actin may be involved in the control of volume-regulated
transport proteins.
Alternatively, the actin cytoskeleton could be part of the volume sensor that
responds to changes in osmotic conditions (Mills, Schwiebert et al. 1994; Henson 1999).
The actin cytoskeleton also may be linked to mechanisms of volume regulation by
specific signal transduction pathways via proteins which control the organization of the
actin cytoskeleton and alter the activity of actin-binding proteins (Mills, Schwiebert et al.
1994; Henson 1999). A comprehensive understanding of cytoskeletal modifications
during cell swelling would provide a more detailed understanding of the mechanisms of
brain cell volume regulation during edema.

Cell Signaling
Cell osmolyte homeostasis and volume regulation must involve a balance between
passive efflux pathways and active membrane transport systems each of which may be
regulated via a variety of signaling mechanisms. In most cells, there are several general
features of intracellular signaling in response to cell swelling (Lim, Bot et al. 2007;
Hoffmann, Lambert et al. 2009). Protein tyrosine phosphorylation is required for
activation of the volume regulated anion channel (VRAC) which allows efflux of
inorganic ions and organic osmolytes. Hypotonicity activates non-receptor protein
tyrosine kinases (e.g. FAK) in addition to receptor tyrosine kinases (leading to activation
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of PI3, Src and MAP kinases). G proteins are involved in RVD in several cell types
(Bender, Neary et al. 1993; Hoffmann, Lambert et al. 2009). Finally, cell swelling
activates signaling pathways associated with hormone and/or growth factor-associated
signal transduction some of which are coupled to VRAC regulation (Lim, Bot et al. 2007;
Hoffmann, Lambert et al. 2009).
Although taurine and electrolyte (K+ and Cl-) release is a common mechanism to
reduce cell volume among many cell types, the molecules signaling release of these
substances during cell swelling appear to be diverse and cell specific. Signaling pathways
may involve fatty acid metabolism, calcium, PKC, and ATP. For example, leukotrienes
activate a RVD pathway following hypotonic challenge in Ehrlich ascites tumor (EAT)
cells (Hoffmann, Lambert et al. 2009). This pathway involves translocation of cPLA2 to
the nuclear membrane, arachadonic acid mobilization and oxidation to LTD 4, and release
and binding of LTD4 to a G protein-coupled receptor which then leads to efflux of taurine
and K+ (Hoffmann, Lambert et al. 2009). In addition to leukotrienes, calcium has been
suggested to play a role in RVD in many cell types (e.g. epithelial cells); however, nonepithelial cells often have no increase in calcium levels revealing that the response is
diverse and that an increase in intracellular calcium, while not required for RVD, may
play a permissive role (Hoffmann, Lambert et al. 2009). In HeLa cells, calcium-induced
taurine release under conditions of hypotonicity is mediated by a novel PKC isoform
(Hoffmann, Lambert et al. 2009). In several cell types, including cultured astrocytes, an
increase in cell volume leads to an increase in calcium and to rapid hydrolysis of
phosphatidylinositol (PI) to form inositol phosphates (IPs) and diacylglycerol (DAG).
DAG then activates PKC (Bender, Neary et al. 1993). In cultured astrocytes, PKC is
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suggested to exert negative feedback on PI hydrolysis and thereby regulate intracellular
calcium and RVD (Bender, Neary et al. 1993). In other cell types (e.g. rat hepatoma cells)
ATP released during osmotic swelling can elicit an increase in intracellular calcium via
binding to its purinergic receptor (Hoffmann, Lambert et al. 2009).
Taurine release, specifically, has been shown to be modulated by Ca2+/CaM,
protein kinases/phosphatases, and reactive oxygen species (Hoffmann, Lambert et al.
2009). Calcium may potentiate swelling-induced taurine efflux via pathways involving
calmodulin (CaM) and calmodulin kinase II (CaMKII), PI3K, and PKC. PKC activation
may either stimulate, decrease, or fail to affect Cl- current in different cell types. In
cultured astrocytes, PKC activation and inhibition also decreases potassium fluxes
(Pasantes-Morales, Cardin et al. 2000). In addition to PKC, tyrosine kinases also play a
role in regulating osmolyte fluxes, including taurine release in swollen cells (Hoffmann,
Lambert et al. 2009). Whereas tyrosine kinase inhibitors block Cl- fluxes and decrease
taurine efflux in cortical astrocytes, tyrosine phosphatase inhibitors potentiate the
pathway (Pasantes-Morales, Cardin et al. 2000).
In addition to mechanisms regulating efflux channels, the signaling pathways
involved in osmolyte accumulation during cell volume regulation have begun to be
uncovered. Many osmolyte transporters have been shown to be regulated by protein
kinases and via protein-protein interactions (Kilberg, Stevens et al. 1993; McGivan and
Pastor-Anglada 1994; Chen, Reith et al. 2004). Protein kinase C and protein kinase A
(PKA) consensus phosphorylation sites in the cytosolic domains of organic osmolyte
transporters signify the possibility of regulation by second messenger systems that could
alter the affinity of transporters for their substrate or change transporter numbers leading
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to changes in transport rate (Clark and Amara 1993; Masson, Sagne et al. 1999). The
transporter for serotonin (SERT) is regulated by secretory carrier membrane protein 2
(SCAMP2) which is an integral membrane protein involved in post-golgi recycling
pathways (Muller, Wiborg et al. 2006). PKC was shown to decrease SERT activity by
causing redistribution of SERT from the plasma membrane to intracellular compartments
(Muller, Wiborg et al. 2006). Subcellular redistribution is thought to be a common
regulatory mechanism for transporters and is consistent with data showing that PKCmediated transport inhibition is associated with a decrease in Vmax with no change in Km
(Masson, Sagne et al. 1999; Chen, Reith et al. 2004). Unfortunately, direct molecular
modifications (e.g. phosphorylation) of the transporter protein by PKC have not been
evaluated.
An isoform of the Na+/H+ exchanger (NHE1) has been shown to be regulated by
various signaling molecules. The NHE1 peptide contains binding sites for CHP, CaM,
tescalcin, ERM proteins, NIK, CAII, 14-3-3 protein, HSP70, SHP-2, PFK-1, and PIP2
(Hoffmann, Lambert et al. 2009). In some cell types, PKC, p38, JNK, and MLCK have
been shown to play roles in the shrinkage-induced activation of NHE1 (Hoffmann,
Lambert et al. 2009). However, like studies of SERT, direct molecular modifications of
the transporter protein by these signaling molecules has not been studied. Vertebrate Na +K+-2Cl- cotransporters (NKCCs) are also regulated by osmotic perturbations via kinase
signaling molecules. NKCC1 interacts with members of the Ste20-related kinases as well
as Ser/Thr protein phosphatases 1 and 2A. It is directly phosphorylated and activated
following osmotic shrinkage (Hoffmann, Lambert et al. 2009). WNK isoforms as well as
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MLCK, JNK, PKC, FAK, and tyrosine phosphorylation have also been implicated in the
regulation of NKCC1 (Hoffmann, Lambert et al. 2009).
The taurine transporter is regulated by various signaling molecules in several cell
types (Hoffmann, Lambert et al. 2009). In oocytes injected with Madin-Darby Canine
kidney (MDCK) cell TauT, PKC activation leads to a decrease in taurine transport and
PKC inhibition leads to an increase in taurine transport (Han and Chesney 2006). Ser-322
was confirmed to be the critical site for PKC phosphorylation in these cells (Han and
Chesney 2006; Han, Patters et al. 2006). Other studies of TauT in cortical neurons,
astrocytes, kidney cells, and macrophages have implicated PKC, PPI-3, cAMP, NO,
TNFα, and LPS as potential intracellular signaling molecules which could modify taurine
accumulation rates (Olson and Martinho 2006b). Olson and Martinho explored the
kinetic and pharmacological characteristics of taurine transport in swollen neurons. Their
results showed that neuronal taurine accumulation was diminished in response to
hypoosmotic swelling and suggested that reduced TauT activity may require
phosphorylation via a protein tyrosine kinase. PKC, a serine/threonine kinase, had no
effect on neuronal taurine accumulation and was therefore unlikely to modify neuronal
TauT activity in the hippocampus in response to osmotic perturbations (Olson and
Martinho 2006a; Olson and Martinho 2006b). While these studies assessed the effects of
various signaling molecules on the kinetics of taurine transport, they stopped short of
assessing direct modifications by these signaling molecules on the TauT peptide.
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Membrane Protein Trafficking
Insertion and removal of membrane transport proteins to and from the plasma
membrane is a common mechanism of transporter regulation in a variety of cell types.
Subcellular redistribution of membrane transporters is well documented in both neurons
and astrocytes. In fact, a common theme for the SLC6 family of neurotransmitter
transporters, to which TauT belongs, is regulation of transport activity via rapid
redistribution to and from the plasma membrane in response to various signals (Chen,
Reith et al. 2004; Muller, Wiborg et al. 2006). The GABA transporter, GAT1 is
accumulated intracellularly in hippocampal neurons upon activation of protein kinase C
(PKC) in parallel with a decrease in transport capacity (Beckman, Bernstein et al. 1999;
Whitworth and Quick 2001). In contrast, GAT1 expression increases on the plasma
membrane in response to direct tyrosine phosphorylation due to a decrease in the rate of
internalization. This is paralleled with an increase in transport activity (Whitworth and
Quick 2001). In other cell types norepinephrine transporter (NET) activity, dopamine
transporter (DAT) activity, serotonin transporter (SERT) activity, and glycine transporter
(GLYT1 and GLYT2) activity can all be decreased via internalization of the proteins
upon PKC activation (McGivan and Pastor-Anglada 1994; Beckman, Bernstein et al.
1999; Whitworth and Quick 2001; Granas, Ferrer et al. 2003; Chen, Reith et al. 2004). In
Xenopus oocytes injected with a neuronal GAT1 clone, PKC activation increased GAT1
transporter activity in association with translocation of the transporter peptide from the
cytoplasm to the plasma membrane (Corey, Davidson et al. 1994).
Other transporters outside the SLC6 family also are regulated via redistribution to
and from the plasma membrane in response to various stimuli. In renal cells the
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betaine/GABA transporter (BGT1) is trafficked to the plasma membrane upon exposure
to hypertonic conditions and may be internalized and retained intracellularly upon return
to isoosmotic conditions (Kempson, Parikh et al. 2003; Kempson and Montrose 2004).
Additionally, glucose transporter activity (GLUT) is modulated via insulin-stimulated
translocation of the protein to and from the plasma membrane (Cushman and Wardzala
1980). Although many signaling molecules, especially PKC, have been implicated as
initiators of trafficking, it remains to be determined if these molecules are activated and
responsible for protein trafficking of TauT and possibly other transporters under
conditions of cell swelling in neurons and astrocytes.

Role of Taurine in Brain Cell Volume Regulation
The sulfur-containing amino acid, taurine (2-aminoethanesulfonic acid) is in
millimolar concentrations in the brain and known to be responsible for regulation of total
brain volume and regulation of cellular volume (Tappaz 2004). Whereas most amino
acids contain a carboxyl group, an amino group, and a side chain all connected to the αcarbon, in taurine the carboxyl group is replaced by a sulphate group. Taurine is found
naturally in many foods but also can be synthesized in mammals from cysteine via
cysteine sulfinic acid (Figure 1) (Tappaz 2004). In this pathway, cysteine is oxidized to
cysteine sulfinic acid by the enzyme cysteine dioxygenase. Cysteine sulfinic acid is then
decarboxylated by sulfinoalanine decarboxylase forming hypotaurine. Hypotaurine is
further oxidized to form taurine (Tappaz 2004).
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Figure 1. Taurine Biosynthesis. Taurine is synthesized in mammals from the amino acid
cysteine. Cysteine is oxidized by cysteine dioxygenase to form cysteine sulfinate.
Cysteine sulfinate is decarboxylated by cysteine sulfinate decarboxylase to form
hypotaurine which is oxidized by hypotaurine dehydrogenase to form taurine.

Taurine plays an important role in volume regulation of both neurons and
astrocytes. In conditions of osmotic edema, studies have demonstrated a net efflux of
taurine from neurons, but an accumulation by astrocytes (Nagelhus, Lehmann et al.
1993). The result is that neurons are able to maintain their cell volume while astrocytes
swell. Taurine also contributes to regulation of total brain volume. During prolonged
hypoosmotic hyponatremia, taurine accumulates in the extracellular space and
subsequently is lost from brain tissue. Likewise in states of dehydration or hypernatremia,
taurine is accumulated intracellularly and contributes to volume regulation under these
conditions (Nagelhus, Lehmann et al. 1993; Lien 1995; Lien and Shapiro 2007). Thus
taurine contributes significantly to both regulation of normal cellular volume and total
brain volume.
Cellular taurine content depends both on the rate of influx and efflux. Cell
swelling increases taurine efflux in both neurons and astrocytes. However, swelling does
not affect taurine uptake in astrocytes while it decreases neuronal taurine uptake over a
period of at least thirty minutes (Sanchez-Olea, Moran et al. 1991; Olson and Martinho
2006a; Olson and Martinho 2006b). Taurine influx and efflux have been shown to occur
through separate membrane pathways in many cell types. Generally, taurine loss occurs
rapidly following hypoosmotic shock via a Na+-independent passive efflux mechanism
that remains ill-defined (Shennan 2008). On the other hand, taurine is accumulated in
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many cells, including astrocytes and neurons, via a specific sodium- and chloridedependent transporter, TauT, which is a member of the SLC6 superfamily of membrane
transporters (Smith, Borden et al. 1992).
TauT has been cloned from several species and tissues. The TauT peptide has
twelve membrane spanning regions and a calculated molecular weight of 72-75 kDa with
several potential sites for phosphorylation and glycosylation (Figure 2) (Smith, Borden et
al. 1992). In kidney cells a specific serine residue, Ser-322, has been reported to be a
critical site for regulation of TauT (Han, Budreau et al. 1999). It is thought that
phosphorylation at Ser-322 by PKC causes a decrease in TauT activity either via a
conformational change or internalization from the plasma membrane.
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Although information is available regarding regulation of kidney TauT, much less
is known about how the taurine transporter is regulated in brain cells. Neuronal and
astrocytic forms of TauT are believed to be similar in structure, but regulation of the
transporter is evidently different in neurons and astrocytes. In vitro swollen neurons have
been shown to decrease taurine accumulation by decreasing the rate of taurine transport;
a response to cell swelling that is qualitatively different from that observed in astrocytes
in which taurine transport is unaffected. In contrast, PKC activation decreases the rate of
taurine transport in astrocytes, but has no effect on taurine transport in neurons (Jones,
Miller et al. 1991; Beetsch and Olson 1996; Olson and Martinho 2006a; Olson and
Martinho 2006b). These observations suggest that differential regulation of neuronal and
astrocytic taurine transporters facilitates net osmolyte and water movement and
contributes to neuronal volume regulation and astrocytic swelling during osmotic brain
edema.

Summary and Rationale for Experiments
In the hippocampus, brain swelling due to physical or chemical insult involves the
movement of fluid into cells. A defining characteristic of brain edema is the presence of
markedly swollen astrocytes while neurons retain their normal volume (Walz, Wuttke et
al. 1984; Torp, Andine et al. 1991; Amundson, Goderie et al. 1992; Nagelhus, Lehmann
et al. 1993; Kanamori, Ross et al. 2002). Since cell volume is maintained via regulation
of intracellular osmolyte content, this observation implies differential regulation of
membrane osmolyte flux in neurons and astrocytes during osmotic edema. This
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observation also may be indicative of a rapid net transfer of intracellular osmolytes from
neurons and other cells (e.g. oligodendrocytes) to astrocytes.
The taurine transporter (TauT) is involved in regulating cell volume by
transporting taurine into cells. A differential pattern of taurine transport regulation in
neurons and astrocytes has been observed in the hippocampus. TauT activity is decreased
in neurons and the cells are able to volume regulate in vivo in response to physical or
chemical insults. In contrast, TauT activity in astrocytes is unchanged and these cells
swell under these conditions. Additionally, PKC decreases astrocyte but not neuronal
TauT activity while tyrosine kinase activity is involved in the decrease in TauT activity
of osmotically swollen neurons (Jones, Miller et al. 1991; Beetsch and Olson 1996; Olson
and Martinho 2006a; Olson and Martinho 2006b). The differential regulation of TauT in
these two cell types may be dependent on two events; post-translational modification of
the TauT protein and redistribution of the TauT protein from the membrane to
intracellular compartments or vice versa. From previous studies, it is possible that a
tyrosine kinase is involved in modification of the hippocampal neuronal TauT and that
PKC is responsible for astrocyte TauT modification.
The primary purpose of this research is to define molecular mechanisms
responsible for regulation and maintenance of neuronal cell volume under pathological
conditions in vivo. Using an in vitro model of osmotic edema, I define the localization of
the taurine transporter in neurons and astrocytes. Also, the intracellular signaling
pathways which regulate the taurine transporter in primary cultures of isolated
hippocampal neurons and astrocytes are characterized and molecular modifications of the
transporter during edema in both cell types are assessed. Experiments integrate studies of
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hippocampal neurons and astrocytes from primary cell culture exposed to hypoosmotic
conditions.
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III. SPECIFIC AIMS AND HYPOTHESIS
Subcellular redistribution of membrane transporters is well documented in both
neurons and astrocytes. Members of the SLC6 family of neurotransmitter transporters, in
particular, are known to be regulated via rapid redistribution to and from the plasma
membrane upon various signals (Chen, Reith et al. 2004; Muller, Wiborg et al. 2006).
GABA transporter (GAT1) activity, norepinephrine transporter (NET) activity, dopamine
transporter (DAT) activity, glycine transporter (GLYT1 and GLYT2) activity, and
serotonin transporter (SERT) activity are all decreased upon activation of PKC as the
transport proteins from the plasma membrane are moved to intracellular compartments
(Beckman, Bernstein et al. 1999; Whitworth and Quick 2001; Granas, Ferrer et al. 2003;
Chen, Reith et al. 2004; Muller, Wiborg et al. 2006). Other transporters, such as the
betaine/GABA transporter (BGT1) and the glucose transporter (GLUT) also are regulated
via membrane trafficking in response to various signals including osmotic perturbations
or changes in substrate availability (Cushman and Wardzala 1980; Kempson, Parikh et al.
2003; Kempson and Montrose 2004). Given the large body of evidence suggesting that
membrane transporter activity can be regulated via trafficking of the proteins to and from
the plasma membrane and intracellular compartments as well as evidence showing that
the decrease in TauT activity in swollen hippocampal neurons is associated with a
decrease in Vmax, TauT activity is likely mediated in a similar fashion. However, the
mechanism of regulation for TauT in response to osmotic perturbations or manipulation
of specific signaling molecules in neurons and astrocytes has not been studied. Therefore,
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our goal was to examine the subcellular distribution of TauT in hippocampal neurons and
astrocytes under normal conditions and conditions of cell swelling.
Signaling pathways involved in altering the activity of the taurine transporter
(TauT) protein are different in neurons and astrocytes. While swollen neurons have been
shown to reduce taurine accumulation by decreasing TauT activity, taurine transport is
unaffected by cell swelling in astroglial cells (Olson and Martinho 2006a; Olson and
Martinho 2006b). In addition, PKC activation decreases the rate of taurine transport in
astroglial cells (and kidney where the specific serine-P has been identified), but has no
effect on taurine transport in neurons (Jones, Miller et al. 1991; Beetsch and Olson 1996;
Olson and Martinho 2006a; Olson and Martinho 2006b). On the contrary, protein tyrosine
kinases have been suggested to play a role in altering taurine transporter activity in
swollen neurons (Olson and Martinho 2006a; Olson and Martinho 2006b). This
differential regulation would facilitate net osmolyte and water movement during osmotic
brain edema. While some studies have assessed the effects of osmotic perturbations or
manipulation of various signaling molecules on the kinetics of the taurine transporter,
none, to our knowledge, have combined these treatments to assess the specific signaling
pathways that are activated by cell swelling in neurons and astrocytes. In addition,
evidence is lacking regarding direct post-translational modifications (PTMs) of TauT
which may alter transporter kinetics. Thus, our objective was to assess the protein
chemistry (i.e. phosphorylation) of TauT under normal conditions and conditions of cell
swelling following activation or inhibition of tyrosine kinases and PKC in both neurons
and astrocytes.
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Hypothesis: The neuronal taurine transporter protein is regulated by a tyrosine
kinase signaling pathway whereas the astroglial taurine transporter is regulated by
serine/threonine kinases. This differential regulation contributes to neuronal volume
regulation and astroglial swelling during osmotic brain edema.

Specific Aim I. Demonstrate that the hippocampal neuronal taurine transporter (TauT) is
sequestered intracellularly in response to cell swelling. Conversely, show that astroglial
TauT is not sequestered intracellularly and remains on the plasma membrane in response
to cell swelling. Examine which kinase signaling pathways mediate membrane trafficking
of TauT in each cell type.

Specific Aim II. Demonstrate that the hippocampal neuronal taurine transporter is altered
via post-translational modifications by signaling pathways involving tyrosine kinases.
Conversely show that the astroglial TauT is altered via post-translational modifications
by signaling pathways involving the PKC family of serine/threonine (Ser/Thr) kinases.
These differences in signaling pathways will be evidenced as differences in
phosphorylation of the transporter protein.
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IV. MATERIALS AND METHODS
Materials
Glycoprotein Deglycosylation Kits, phorbol-12-myristate-13-acetate (PMA),
genistein, sodium orthovanadate, and chelerythrine chloride were purchased from
Calbiochem (Darmstadt, Germany). Bicinchoninic acid solution, Mammalian Cell Lysis
Kits, bovine serum albumin, alkaline phosphatase-conjugated anti-fluorescein, and CDPStar® Chemiluminescent Substrate were purchased from Sigma Aldrich (St Louis, MO).
The FractionPREP Cell Fractionation System was from BioVision (Mountain View,
California). The Immunoprecipitation Kit was from Roche (Mannheim, Germany). Tau1
peptide was from Chemicon/EMD Millipore (Billerica, MA). Anti-Taurine transporter
primary antibody and anti-Na+/K+-ATPase were purchased from Millipore (Billerica,
MA). Anti-β-actin antibody was from Rockland Immunochemicals (Gilbertsville, PA).
Anti-HSP-70 and anti-histone H1 antibodies were from Santa Cruz Biotechnology (Santa
Cruz, CA). FITC-conjugated goat anti-rabbit secondary antibody was purchased from
Jackson ImmunoResearch (West Grove, PA). StrepTactin AP-conjugate was from Bio
Rad (Hercules, CA). The Cell Surface Protein Isolation Kit was from Pierce (Rockford,
IL). Fluoro-gel aqueous mounting medium was purchased from BioMeda Corporation
(Foster City, CA). Annexin V and DAPI were from Molecular Probes (Grand Island,
NY). All other chemicals were purchased from Fischer Scientific (Pittsburgh, PA) and
were the highest grade available. Nano-pure water (dH2O) was prepared with a Barnstead
Water Purification System using deionized and distilled water as the input water supply.
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Cell Culture
Primary hippocampal astrocyte cultures and primary hippocampal neuron cultures
were prepared from Sprague Dawley rats and maintained as previously described (Olson
and Holtzman 1980; Beetsch and Olson 1996; Olson and Martinho 2006a; Olson and
Martinho 2006b). All procedures were approved by the Laboratory Animal Care and
Utilization Committee of Wright State University and conform to the Guide for the Care
and Use of Laboratory Animals. Cells were grown on 100 mm plastic culture dishes at an
initial plating density of approximately 6 x 104 cells/cm2. Culture medium was changed
twice weekly for 2 weeks.
For astrocyte cultures, cells were derived from 2-4 day-old rat pups. Rat pups
were anesthetized with CO2, washed with 70% ethanol, and then decapitated and the
hippocampi dissected using sterile techniques. Hippocampi were pooled and exposed to
0.125% trypsin for 15 min then triturated, filtered, and centrifuged. The resulting cells
were resuspended in medium consisting of 80% minimal essential medium (MEM) plus
20% newborn calf serum and containing antibiotics (50 U/ml penicillin, 50 mg/ml
streptomycin), four times the normal concentration of MEM vitamins, twice the normal
concentration of amino acids and 1.6 mg/ml additional sodium bicarbonate. Unattached
cells and debris were removed from the dishes by aspiration 1-2 days after plating and
culture medium was replaced with 90% MEM plus 10% newborn calf serum plus the
additional antibiotics, vitamins, amino acids, and bicarbonate. This medium was used for
subsequent feedings twice weekly. Experiments were performed on cells after 14-28 days
in vitro.
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Hippocampal neuron cultures were prepared from rat fetuses at gestational day
18-19. Pregnant females were anesthetized with isoflurane (5% induction, 2%
maintenance at 2 L air/min) and a sterile laparotomy was performed. Animals were
determined to be unresponsive to painful stimuli prior to initiation of invasive
procedures. Fetuses were removed from the uterus and transferred to ice-cold divalentcation-free-Hank’s balanced salt solution (DCF-HBSS). Fetuses were decapitated and the
hippocampi dissected and pooled together. Hippocampi were exposed to 0.125% trypsin
for 15 min at 37°C in DCF-HBSS then rinsed and triturated. The resulting suspension
was centrifuged and the cells were resuspended and plated in DMEM plus 10% horse
serum and antibiotics described above. After 4 h medium was changed to NeurobasalTM
medium containing antibiotics and B27 additives. Medium was changed twice weekly by
removing one-half of the culture medium and replacing it with fresh medium. Cultures
were used for experimentation after 10-14 days in vitro.

Immunocytochemistry
Cells grown on glass coverslips were treated for 30 min with isoosmotic or
hypoosmotic PBS with or without activators or inhibitors of PKC and tyrosine kinases.
Coverslips were rinsed twice with PBS of the same osmolarity. Cells were fixed for 15
min with 4% paraformaldehyde in immunostaining buffer containing 137 mM NaCl and
10 mM Na2HPO4 at pH=7.42. Fixative was removed and coverslips rinsed two more
times with immunostaining buffer. Non-specific antigen sites were blocked with a 30 min
exposure to 20% pre-immune goat serum. Then coverslips were rinsed twice for 5 min
using immunostaining buffer. Primary antibody (anti-TauT 1:375) was added and
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allowed to incubate for 60 min. Coverslips were rinsed twice with immunostaining buffer
followed by incubation with secondary antibody (goat anti-rabbit FITC 1:100) for 60
min. Coverslips were again rinsed twice (5 min each) with immunostaining buffer and
affixed onto glass slides with an aqueous mounting medium (BioMeda Corporation,
Foster City, CA, USA) for illumination with epifluorescence and assessment of taurinelike immunostaining.

Determination of ATP
An ATP Determination Kit (Molecular Probes, Eugene, OR) was used for
quantitative determination of ATP. This method takes advantage of the bioluminescence
reaction between recombinant firefly luciferase and its substrate D-luciferin in the
presence of ATP. First, a standard reaction solution was made using appropriate volumes
of dH2O, 20X Reaction Buffer, 0.1 M dithiothreitol (DTT), 10 mM D-luciferin, and
firefly luciferase. Low-concentration ATP standard solutions (0-20 µl 5 mM ATP) were
prepared in dH2O and used to generate a standard curve for ATP concentrations. A
volume (100 µl) of standard reaction solution was added to each sample tube containing
the cell lysates (see Cell Swelling and Lysis, page 34) and the luminosity read on a LKB
Wallac 1250 Luminometer (LKB Instruments, Mt. Waverley, Vic). ATP concentrations
were calculated based on the standard curve.

Annexin V Assay
Neurons grown on glass coverslips were treated for 30 min in isoosmotic
conditions + 1 µM PMA. Coverslips then were rinsed twice with warm isoosmotic PBS.
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Cells were incubated with 5% Annexin V for 1 h at 37°C. Coverslips were rinsed again
with warm isoosmotic PBS and then fixed with 1% paraformaldehyde for 15 min.
Fixative was removed and coverslips rinsed twice more with isoosmotic PBS and cells
were then incubated with 5 mg/ml 4’,6’-diamidino-2-phenylindole (DAPI) for 15 min.
Following incubation, coverslips were rinsed twice with dH2O and then affixed onto
glass slides with an aqueous mounting media (BioMeda Corporation, Foster City, CA,
USA) for illumination with epifluorescence.

Cell Swelling and Lysis
On the day of experiments, primary astrocyte and neuron cultures were washed
twice with 1-2 ml isoosmotic (290 mOsm) phosphate-buffered saline (PBS). Cells were
then incubated for 30 min at 37C in 8 ml PBS containing 90 mM NaCl, 2.7 mM KCl,
1.0 mM CaCl2, 0.5 mM MgCl2, 3.2 mM Na2HPO4, 0.5 mM KH2PO4, 5.5 mM glucose
(pH = 7.3) plus additional NaCl to adjust the osmolality to 290 mOsm (isoosmotic) or
200 mOsm (hypoosmotic). For pharmacological experiments, 1 µM phorbol-12myristate-13-acetate (PMA), an activator of protein kinase C, or 1 mM orthovanadate, a
protein tyrosine phosphatase inhibitor was added to isoosmotic PBS or 2.5 µM
chelerythrine, an inhibitor of PKC, or 100 µM genistein, a tyrosine kinase inhibitor was
added to hypoosmotic PBS. In all cases, drugs were added to the PBS of the appropriate
osmolarity when the osmotic treatment was initiated. For some experiments, cells were
pre-treated for 30 min in isoosmotic PBS plus 100 µM genistein prior to incubation of the
cells in hypoosmotic PBS containing 100 µM genistein for 30 min. At the end of the
treatment period the PBS was aspirated and the cells washed twice with 1-2 ml ice cold
PBS of the same osmolarity. An appropriate volume of lysis buffer (Tris-EDTA buffer,
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NaCl, SDS, deoxycholic acid, Igepal CA 630, and Protease Inhibitor Cocktail) was added
to each dish and cells were carefully scraped into microcentrifuge tubes and incubated on
ice for 10 min. Cells were disrupted by sonication with five 1 sec bursts then centrifuged
for 10 min at 10,000 × g. The supernatant was used as the protein extract.

Determination of Total Protein
Total protein concentration of each cell lysate was calculated based on a standard
curve using a BCA assay (Sigma). Ten microliters of each sample was combined with
90 μl of water and 1 ml of BCA solution. Standards and samples were incubated at 40°C
for 25 min. Concentration of protein was calculated using a Bio-Tek ELx800 Universal
Microplate reader.

Protein Deglycosylation
Proteins were deglycosylated using a Glycoprotein Deglycosylation Kit
(Calbiochem, Darmstadt, Germany). Two hundred micrograms of total protein was
dissolved in 30 µl or 35 µl of deionized water (denaturing or non-denaturing protocol,
respectively). Ten microliters 5X Reaction Buffer and 2.5 µl Denaturation Solution
(denaturing protocol only) were added and mixed gently. 2.5 µl Triton X-100 detergent
solution (denaturing protocol only) then was added and mixed gently followed by 1 µl
each of N-Glycosidase F, α2-3,6,8,9-Neuraminidase, endo-α-N-acetylgalactosaminidase,
β1,4-galactosidase, and β-N-acetylglucosaminidase. The mixture was incubated for 24 h
at 37ºC and then analyzed by western blot analysis.
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Preparation of 10-well Gels
For some experiments, 10% and 5% polyacrylamide gels were prepared using
appropriate amounts of water, acrylamide, tris, 10% sodium dodecylsulphate (SDS),
TEMED, and ammonium persulfate. The 10% resolving gel was poured into glass
cassettes to the appropriate height and allowed to polymerize. A short 5% stacking gel
was poured over the polymerized resolving gel and a comb inserted into the cassette
between the glass spacers before the 5% gel was allowed to polymerize. For the majority
of experiments, pre-cast 10% polyacrylamide 10-well mini-gels or pre-cast 10-20%
polyacrylamide CriterionTM TGXTM gels were purchased from Bio-Rad.

1D SDS-PAGE and Immunoblotting
Sample volumes containing a known amount of total protein were mixed 1:1 (v/v)
with sample buffer (containing 0.5 M Tris-HCl (pH=6.8), glycerol, 10% SDS, 0.5%
bromophenol blue, and 5% -mercaptoethanol). Samples were boiled for 5 min to
denature proteins and then loaded into the wells of the polyacrylamide gels. Standard
proteins of known molecular weights were loaded into separate lanes. Electrophoresis
was run at 100 V for 85-100 min until the dye front reached the end of the gel. Following
electrophoresis, proteins were transferred to PVDF membranes at 10°C using 30 V for
18 h.
PVDF membranes were rinsed with T-TBS (0.15 M NaCl, 0.02 M Tris-HCl
pH=7.5 and 0.05% Tween-20) for 5 min and then incubated with 5% (w/v) blocking
buffer (nonfat dry milk powder in T-TBS) for 1 h with continuous rocking. Blocking
buffer was removed and the membrane incubated with primary antibodies to TauT
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(1:1000) and β-actin (1:1000) in TBS (T-TBS without Tween-20) for 1 h with rocking.
To assess the specificity of anti-TauT binding, some membranes were incubated with a
solution in which the primary antibody was pre-absorbed with its peptide antigen (Tau1)
for 1 h. The membrane then was washed with T-TBS (four times, 5 min each) with
continuous rocking. TBS containing the secondary antibody (FITC conjugated goat antirabbit, 1:2500) and StrepTactin AP-conjugate (1:5000, to label the molecular weight
standards) was added to the membrane for 1 h with rocking. The membrane was again
washed four times with T-TBS and then TBS containing the tertiary antibody (AP
conjugated anti-fluorescein, 1:1000) was added to the membrane for 30 min with
continuous rocking.
Blots were imaged using ECL substrate and a Fujifilm LAS-3000
chemiluminescence imager or a Bio-Rad ChemiDocTM XRS+ imager. Membranes were
exposed for 15 min and images were taken at 30 sec increments for subsequent analysis
of band position and density using ImageJ software.

Dot Blot Analysis
Some samples were analyzed using dot blots rather than western blots. Briefly, a
pre-wet PVDF membrane was placed in the dot blot apparatus and the apparatus clamped
and attached to a vacuum. Equal amounts of total protein for each sample were dissolved
in 1 ml D/D (distilled and deionized) water and loaded into appropriate wells of the dot
blot apparatus. Dilutions of untreated and unfractionated cells with 100 µg, 50 µg, or
25 µg protein also were loaded and BSA and Tau1 peptide were used as negative and
positive controls, respectively. After sample loading, the vacuum was applied and
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allowed to run until no liquid remained. The membrane was immediately transferred to
T-TBS (0.15 M NaCl, 0.02 M Tris-HCl, pH=7.5 plus 0.05% Tween-20) and probed with
antibodies as described above.

Subcellular Fractionation
Neuron and astrocyte cell lysates were separated into subcellular fractions by
differential centrifugation using a FractionPREP Cell Fractionation System (BioVision,
Mountain View, California). For each sample, the protein extract was mixed with 400 µl
of Cytosol Extraction Buffer-Mix (CEB-Mix containing DTT and Protease Inhibitor
Cocktail) and mixed well. The resulting sample was incubated on ice for 20 min with
gentle tapping 3-4 times every 5 min, and then centrifuged at 700 × g for 10 min. The
supernatant was collected and saved on ice as the Cytosolic Fraction. The pellet was
resuspended in 400 µl of ice cold Membrane Extraction Buffer-A Mix (MEB-A Mix
containing DTT and Protease Inhibitor Cocktail). The sample was mixed well by
pipetting several times and vortexed for 10-15 sec. Membrane Extraction Buffer-B
(22 µl) was added and the sample vortexed for 5 sec. The sample then was incubated on
ice for 1 min, vortexed again for 5 sec, and then centrifuged at 1,000 × g for an additional
5 min. The supernatant was transferred to a pre-chilled tube and kept on ice as the
Membrane/Particulate fraction while the pellet was resuspended in 200 µl of ice cold
Nuclear Extraction Buffer-Mix (NEB-Mix containing DTT and Protease Inhibitor
Cocktail). This solution was vortexed for 15 sec and then incubated on ice for 40 min
with vortexing for 15 sec every 10 min. The sample was then centrifuged for 10 min at
10,000 × g, and the supernatant transferred to a pre-chilled tube and kept on ice as the
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Nuclear fraction. The pellet was dissolved in 100 µl 0.2% SDS containing 10 mM DTT
and kept on ice as the Cytoskeletal Fraction. All fractions were stored at -80ºC for future
use. On the day of experiments, samples for each fraction were loaded into separate wells
of a 10% polyacrylamide gel and electrophoresis with western blotting was completed as
described above. Other samples were loaded into separate wells of a dot blot apparatus,
transferred onto a PVDF membrane via vacuum suction and probed with antibodies as
described above. As a control, some membranes were probed with antibodies for known
markers of cellular fractions. Anti-Hsp70 was used to mark proteins from the cytosol,
anti-Na+/K+-ATPase marked membrane and particulate structures, anti-histone H1
marked the nucleus, and anti-β-actin marked the cytoskeleton. Blots were imaged as
described above and subsequently analyzed for band position and density using ImageJ
software. Density measurements for each fraction were taken relative to the density
measured for 100 µg protein of raw lysate and corrected for total protein of each fraction.

Cell Surface Biotinylation
Biotinylation experiments were conducted using a cell surface protein isolation kit
(Thermo Scientific, Rockford, Illinois). Culture medium was removed from confluent
cells and the dishes washed twice with Biotinylation Reaction Buffer (BRB) (0.1 M
sodium phosphate, 0.15 M NaCl; pH=7.2). Following experimental treatments, biotin
solution (4 mg/ml, final concentration, Sulfo-NHS-SS-Biotin in BRB) was added to each
dish and dishes placed on a rocking platform and gently agitated for 30 min at 4°C.
Quenching Solution was added to each dish to stop the reaction. Cells were gently
scraped into the solution and dish contents transferred to a single 50 ml conical tube. All

40

dishes were rinsed with TBS (0.025 M Tris, 0.15 M NaCl; pH=7.2) and the rinse volume
added to the transferred cells. Cells were centrifuged at 500 × g for 3 min and the
supernatant discarded. The cell pellet was resuspended in 5 ml TBS, centrifuged at
500 × g for 3 min, and the supernatant discarded. Lysis Buffer containing protease
inhibitors was added and the cell pellet transferred in the lysis solution to a 1.5 ml
microcentrifuge tube. Using low power sonication to prevent foaming, cells were
disrupted on ice using five 1-sec bursts and then incubated for 30 min on ice, vortexing
every 5 min for 5 sec. To improve solubilization efficiency, additional sonications were
performed during the incubation. Cell lysate was centrifuged at 10,000 × g for 2 min at
4°C and the clarified cell lysate transferred to a new tube.
A spin column was inserted into a collection tube and 500 μl of NeutrAvidin
Agarose slurry was added to the column followed by centrifugation for 1 min at
1,000 × g. Flow-through was discarded and 500 μl of Wash Buffer was added (twice) to
the column and centrifuged for 1 min at 1,000 × g with the flow-through discarded.
Clarified cell lysate was added to the gel followed by incubation for 60 min at room
temperature with end-over-end mixing. The column then was centrifuged for 1 min at
1,000 × g and flow-through discarded. Wash Buffer containing protease inhibitors was
added to the column and mixed by inverting. The column then was centrifuged for 1 min
at 1,000 × g. The flow-through was discarded and the rinse with Wash Buffer repeated 3
times. To elute the bound protein, 400 μl of SDS-PAGE Sample Buffer (62.5 mM TrisHCl, pH 6.8, 1% SDS, 10% glycerol) containing 50 mM DTT was added to the column
and incubated in a heat block at 95°C for 5 min. The column was centrifuged for 2 min at
1,000 × g. Bromophenol blue was added to the final elutate and the resulting solution
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analyzed for TauT by western blot as described above. Band densities were background
subtracted and normalized to the density of TauT present in the raw cell lysate.

Immunoprecipitation
TauT was immunoprecipitated from cell lysates incubated under isoosmotic or
hypoosmotic conditions with or without activators or inhibitors of PKC or tyrosine
kinases using an Immunoprecipitation Kit (Roche, Mannheim, Germany). Following
treatments, adherent cells were washed with PBS followed by addition of lysis buffer
(containing protease and phosphatase inhibitors). Cells were scraped to one side of the
dish and transferred in lysis buffer to a Dounce homogenizer pre-chilled on ice. The
samples were homogenized using a pestle by repeated strokes (approximately 10). The
homogenized suspension then was centrifuged at 10,000 × g for 10 min at 4°C. The
supernatant was transferred to a fresh microcentrifuge tube. To reduce background
caused by non-specific adsorption of irrelevant cellular proteins to protein A-agarose, a
pre-clearing step was performed. To the sample was added 50 µl of homogenous protein
A-agarose suspension and this mixture was incubated for 1 h at 4°C on a rocking
platform. Beads were pelleted by centrifugation at 10,000 × g for 20 sec. The supernatant
was transferred to a fresh tube and an appropriate amount of antibody (anti-TauT, 1:375)
added and allowed to incubate with gentle rocking for 3 h at 4°C. Another 50 µl of
homogenous protein-A agarose was added and allowed to incubate overnight at 4°C on a
rocking platform. Complexes were collected by centrifugation at 10,000 x g for 20 sec in
a microcentrifuge. Supernatant was removed and beads resuspended in Wash Buffer 1
and allowed to incubate for 20 min. Complexes were collected by centrifugation at
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10,000 × g for 20 sec in a microcentrifuge. Supernatant was removed and beads
resuspended in another aliquot of Wash Buffer 1 and allowed to incubate for 20 min.
Complexes were collected by centrifugation at 10,000 × g for 20 sec in a microcentrifuge.
Supernatant was removed and beads resuspended in Wash Buffer 2 and allowed to
incubate for 20 min. Complexes were collected by centrifugation at 10,000 × g for 20 sec
in a microcentrifuge. Supernatant was removed and beads resuspended in another aliquot
of Wash Buffer 2 and allowed to incubate for 20 min. Complexes were collected by
centrifugation at 10,000 × g for 20 sec in a microcentrifuge. Supernatant was removed
and beads resuspended in Wash Buffer 3 and allowed to incubate for 20 min. The beads
were pelleted and the supernatant removed. Gel-loading buffer (containing 5% βmercaptoethanol) was added to the agarose and the protein denatured by heating to 100°C
for 3 min. Protein A-agarose was removed by centrifugation at 10,000 × g for 20 sec at
25°C and the supernatant containing the protein sample transferred to a fresh tube. An
aliquot of the immunoprecipitated protein was analyzed by western blot using methods
described above with antibodies specific for phosphorylated forms of serine, threonine,
and tyrosine. Band densities were background subtracted and normalized to the density of
TauT present in the raw cell lysate of the corresponding osmotic treatment.

Proteomic Assays
Proteomic assays were performed at the Wright State University Proteome
Analysis Laboratory (PAL) by analyzing patterns of protein levels in the samples using
Bruker Autoflex III MALDI-TOF/TOF Mass Spectrometry. Proteins were initially
separated by 1-dimensional or 2-dimensional SDS-PAGE, followed by tryptic enzymatic
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digestion to generate peptides. The peptides were analyzed by MALDI-TOF/TOF MS for
identification of specific peptides of interest from TauT and to detect post-translational
modifications (PTM) of those peptides.

Sample Preparation for 2D SDS-PAGE
To facilitate preparation of a low conductivity sample suitable for isoelectric
focusing (IEF) and 2D gel electrophoresis, a ReadyPrepTM 2D clean up kit (Bio Rad,
Hercules, California) was used to remove ionic detergents, salts, nucleic acids, and lipids
from the cell lysates. Precipitating Agent 1 (300 µl) was added to a volume of 100 µl of
sample (cell lysate), vortexed, and incubated on ice for 15 min. Precipitating Agent 2
(300 µl) was then added to the mixture, vortexed and centrifuged at 13,000 x g for 5 min.
Supernatant was removed and the pellet washed with Wash Reagent 1. The sample was
centrifuged at top speed for 5 min and the supernatant discarded. The pellet was washed
with dH2O followed by a brief vortex and addition of Wash Reagent 2 with Wash 2
Additive. The mixture was vortexed and then incubated at -20°C for 30 min with
vortexing for 30 sec every 10 min. After the incubation, the sample was centrifuged at
top speed for 5 min and the supernatant discarded. The pellet was air-dried for 5 min then
resuspended in an appropriate volume of 2D rehydration/sample buffer. The sample was
vortexed and incubated at room temperature for 5 min followed by centrifugation at top
speed for 5 min at room temperature to clarify the protein sample. The supernatant was
saved and used directly for IEF in immobilized pH gradient (IPG) strips.
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Isoelectric Focusing
Clarified samples were used directly for IEF using 11 cm, pH 3-10 IPG strips.
Samples that were suspended in 2D rehydration/sample buffer were loaded into adjacent
channels of a rehydration/equilibration tray. An Escherichia coli control sample also was
loaded into a channel of the rehydration/equilibration tray. The IPG strip was gently
placed gel side down onto the sample. IPG strips were left to rehydrate for at least 30 min
before overlaying each strip with 2 ml mineral oil. The rehydration/equilibration tray was
covered and the IPG strips left to rehydrate overnight. Paper wicks were placed at both
ends of the channels in a PROTEAN IEF focusing tray to cover the wire electrodes and
then each wick was wetted with nanopure water (Bio Rad, Hercules, CA). Mineral oil
was drained from the IPG strips and the strips transferred to the corresponding channel in
the focusing tray, gel side down. Each strip was covered with 2 ml mineral oil, the lid
placed onto the tray, and the focusing tray placed into the PROTEAN IEF cell. A threestep protocol was used with a default cell temperature of 20°C and a maximum current of
50 µA/gel. Step 1 was a linear ramp in current with a maximum voltage of 250 V for 20
min. Step 2 was a linear ramp for 2.5 h at 8,000 V. Step 3 was a rapid ramp at 8,000 V
for 20,000-35,000 V•h. Once electrophoresis was complete, the IPG strips were removed
from the focusing tray and placed gel side up into a clean, dry rehydration/equilibration
tray. The tray was covered and placed in a -80°C freezer for storage.

IPG Equilibration and 2D SDS-PAGE
A volume of Equilibration Buffer 1 from the ReadyPrepTM Kit was added to each
channel containing a thawed IPG strip and allowed to incubate on an orbital shaker for 10
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min. The Equilibration Buffer 1 was discarded and a volume of Equilibration Buffer 2
added and allowed to incubate on an orbital shaker for 10 min. Equilibration Buffer 2 was
discarded and the IPG strips washed briefly in 1X Tris-glycine-SDS running buffer
before being placed gel side up into the IPG well of an SDS-PAGE 10-20% CriterionTM
TGXTM precast gel (Bio-Rad, Hercules, California). Overlay agarose was pipetted
overtop of the IPG strip in the IPG well of the gel and allowed to solidify 5 min.
Molecular weight standards were loaded into the standard well of the gel. Once the
agarose solidified, the gels were mounted into the gel box and the reservoirs filled with
1X Tris-glycine-SDS running buffer. Electrophoresis was performed at 200 V until the
dye front reached the end of the gel (approximately 65 min).

Staining of 1D and 2D Gels
Following electrophoresis, some gels were used for western blotting and probed
with anti-TauT (1:1000). For other gels, protein spots were visualized using GelCode®
Blue Stain reagent (Thermo Scientific, Rockford, Illinois). Gels were placed in a clean
tray and fixed in 50% methanol plus 7% acetic acid for 15 min. Following fixation, gels
were washed three times for 5 min with dH2O. GelCode® Blue stain reagent was added
(50 ml/gel) and protein bands allowed to develop to maximum intensity for 1 h. To
enhance staining sensitivity, gels then were washed with dH2O (changing multiple times)
for 1 h. Protein spots/bands were cut out of the gels and used for in-gel digestion and
mass spectrometry.
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In-Gel Digestion
An in-gel digest was performed using modified methods of Schevchenko, et al.
(1996) (Shevchenko, Wilm et al. 1996). Proteins from various samples (e.g. treated with
isoosmotic or hypoosmotic PBS) were first resolved by 1D or 2D-SDS-PAGE, and
protein spots visualized by GelCode® Blue stain as described above. A corresponding
western blot stained for TauT was used to choose protein spots corresponding to TauT.
The protein spots were excised from the gel and washed in 50 mM NH4HCO3 for 10 min.
The supernatant was removed and replaced by a 1:1 (v/v) mixture of 50 mM
NH4HCO3:CH3CN for 10 min to shrink the gel pieces. This step was repeated and the gel
pieces dried in a vacuum centrifuge for 5 min. Then 10 mM DTT in 25 mM NH4HCO3
(final concentration) was added for 60 min at 37°C to reduce cysteine. The sample was
allowed to cool. Then 55 mM iodoacetamide (10 mg/ml) in 25 mM NH4HCO3 was added
and the gel pieces were incubated for 45 min at 37°C in the dark to alkylate cysteine. The
gel pieces then were washed with 25 mM NH4HCO3 for 10 min and the supernatant
removed. Gel pieces were dehydrated in a 1:1 (v/v) mixture of 50 mM NH4HCO3:CH3CN
twice and dried in a vacuum centrifuge for 5 min. Gel pieces were rehydrated in digestion
buffer containing 20 ng/µl Promega sequencing grade modified porcine trypsin in 25 mM
NH4HCO3. Buffer without trypsin was added to cover the gel pieces and digestion
allowed to proceed overnight at 37°C. After a short centrifugation the supernatant was
removed and saved in a fresh microcentrifuge tube. Tri-fluoroacetic acid (TFA, 0.3%)
was added to saturate the gel pieces and protein extracted with 50% CH3CH containing
0.3% TFA three times for 10 min each. The supernatants from each extraction were
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combined and the volume reduced to 10 µl in a vacuum centrifuge. The sample was
stored at -20°C until ready for ZipTip cleanup.

MALDI-TOF/TOF Mass Spectrometry
For MALDI-TOF/TOF MS, samples were prepared using standard protein
extraction methods. Cellular proteins were separated by 1D or 2D-SDS-PAGE and
stained with GelCode® Blue stain. The bands in the range approximating the mass and pI
of TauT as well as numerous other protein spots were excised with a Spot Picker
(TheGelCompany, San Francisco, CA) and the proteins in the gel digested as described
above. Following digestion, proteins were de-salted and concentrated using ZipTip-based
technology. For unphosphorylated peptides, we used a C18 ZipTip; for phospho-peptides,
we used a Protea TiO2 (Morgantown, WV.) tip. The eluates from these zip-tipped
samples were mixed with alpha-cyano-4-hydroxycinnamic acid (CHCA) matrix, applied
to a MTP 384 brushed-steel target plate, and analyzed on an Autoflex MALDI-TOF/TOF
MS. Bruker LIFT® and CID were used to generate protein/peptide sequences for peaks of
interest. The software averages 1000 randomized laser shots over 5 positions (200
shots/position). Other parameters, e.g., laser power, mass range, and lag focusing were
set after preliminary testing. MS/MS based laser-induced dissociation (Bruker LIFTTM)
was used for fragmentation. As with all MALDI-TOF analysis, calibration spots
containing a peptide/protein mix from Bruker were utilized and the Autoflex was
calibrated often to ensure high quality data. All peptide mass fingerprinting, CID and
LIFT data were analyzed by searching the MASCOT server at the WSU-PAL.
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Database Searching
Database searching was done using the Mascot Search engine (Matrix Science,
London, United Kingdom). The data were searched against the Mascot, Swiss
Proteomics, or NCBInr database with a mass accuracy of 0.3 Da for the parent ion (MS)
and 0.3 for the fragment ions (MS/MS). Peptides were constrained to be tryptic with a
maximum of two missed cleavages. Fixed modifications were carbamidomethylation of
Cys, whereas oxidation of methionine and phosphorylation of serine, threonine, and
tyrosine were considered as variable modifications.

Statistical Analyses
Data were analyzed using SAS 9.3 (Cary, North Carolina). Quantitative data are
expressed as mean ± SEM of results obtained from replicate experiments. Differences in
mean values were measured using a one-way ANOVA followed by Tukey’s HSD for
post hoc comparisons. Log transformations were applied when necessary. When
transformations were not appropriate, the non-parametric Kruskal-Wallis Test was used
with the appropriate post hoc tests. Values were assumed to be significantly different if
p < 0.05.
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V. RESULTS
Identification of the Taurine Transporter Protein in Hippocampal Neurons.
The presence of the taurine transporter (TauT) protein in primary hippocampal neurons
was demonstrated using western blots (Figure 3A). Lanes were loaded with various
concentrations of total protein (10 µg, 20 µg, and 40 µg) from raw cell lysate and band
densities for TauT and β-actin were measured to evaluate the linearity of label intensity
relative to protein loading (Figure 3B). Western blot analysis showed a TauT band at ~98
kDa with densities that increased with increasing protein loading. A similar increase in
intensity with protein loading was seen for β-actin found at ~42 kDa.
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Figure 3. The Taurine Transporter was Present in Hippocampal Neurons. Western
blot demonstrated the presence of the taurine transporter (TauT) in primary hippocampal
neuron cultures at ~98 kDa (A). Lanes were loaded with 10 µg, 20 µg, and 40 µg of
protein. Band densities for TauT and β-actin increased with increased protein loading (B).
MW = molecular weight standard ladder.

Since the molecular weight of the TauT protein in these western blots was greater
than the 72-75 kDa molecular weight calculated from the amino acid sequence of TauT
(Smith, Borden et al. 1992), we considered that the protein may remain glycosylated
following cell lysis. To examine this, neuronal cell lysates were treated with
deglycosylating enzymes (N-glycosidase F, α2-3,6,8,9-neuraminidase, endo-α-Nacetylgalactosaminidase, β1,4-galactosidase, and β-N-acetylglucosaminidase) prior to
western blot analysis.
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Results from the deglycosylation experiments showed that when cells were
treated with both N-linked and O-linked enzymes (Figure 4), a band for TauT was found
at ~58 kDa. When treated only with N-linked enzymes, a band for TauT was found at
~81 kDa. The decrease in molecular weight of deglycosylated TauT as compared with
that of non-deglycosylated TauT indicated that TauT remained glycosylated following
cell lysis. In addition, the smaller decrease in molecular weight of TauT when only Nlinked deglycosylating enzymes were used indicated that the glycosylation was due to a
combination of N-linked and O-linked sugars.

Figure 4. Neuronal TauT Molecular Weight Decreased in the Presence of
Deglycosylating Enzymes. Raw cell lysate showed an average TauT MW of ~98 kDa
(n=3). When treated with N-linked deglycosylating enzymes (n=2) the average TauT
MW decreased to ~81 kDa. In the presence of both N- and O-linked deglycosylating
enzymes (n=3) the average TauT MW was ~58 kDa. The arrow on the y-axis indicates
the predicted 72-75 kDa MW for TauT. Data were analyzed using the Kruskal-Wallis
Test and show a significant difference relative to the molecular weight of the raw lysate
(*p < 0.05).
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The presence of TauT in hippocampal neuron cultures was further demonstrated
by immunostaining. Cells on glass coverslips were treated under isoosmotic or
hypoosmotic conditions in the presence or absence of pharmacological agents (used in
studies described later in this document) for 30 min then fixed, blocked, and incubated
with an antibody against TauT (1:375). FITC-conjugated goat anti-rabbit
immunoglobulin (1:100) was used as the secondary antibody. Immunostaining revealed
strong TauT staining in cell cultures. TauT staining was present throughout the entire cell
i.e. the cytoplasm and cell membranes (Figure 5).
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Figure 5. Immunofluorescence of TauT in Hippocampal Neurons. Cells shown in (A)
were treated under hypoosmotic conditions and cells shown in (B) were treated under
isoosmotic conditions in the presence of 100 µM genistein for 30 min then fixed,
blocked, and incubated with anti-TauT antibody. Immunostaining revealed strong TauT
staining throughout the entire cell.

Neuronal Taurine Transporter Expression was not Altered by Hypoosmotic
Swelling. To determine the effects of swelling on neuronal TauT, neuronal cell cultures
were incubated under isoosmotic or hypoosmotic conditions for 0, 30, or 60 min and cell
lysates were prepared for western blot analysis (Figure 6A). A band for TauT was found
at ~98 kDa and similar TauT band densities were observed for each treatment (Figure
6B). Thus, hypoosmotic swelling did not alter the overall expression of neuronal TauT.

54

Figure 6. Taurine Transporter Expression was not Altered by Hypoosmotic
Swelling. Neuronal cultures were incubated under isoosmotic or hypoosmotic conditions
for 30 or 60 min. Baseline values are from untreated cultures. Western blot analysis
showed a band at ~98 kDa (A) in all conditions with similar TauT band densities relative
to β-actin (B). There was no significant difference in TauT band density under any
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treatment condition. Values are mean ± SEM of three independent determinations. Data
were analyzed using the Kruskal-Wallis Test.
Viability of Neuronal Cell Cultures Following Pharmacological Treatments. To
assess whether the pharmacological treatments used in these experiments affected cell
viability, a luciferin-luciferase bioluminescence assay was performed for quantitative
determination of cellular ATP. Pharmacological activators and inhibitors of tyrosine
kinases and PKC were incubated with the cell cultures under isoosmotic conditions for 30
min. The cells were returned to media and allowed to recover for 24 h. When compared
to baseline values (no treatment), there was a significant decrease in ATP following both
isoosmotic and hypoosmotic treatments (p < 0.05) (Figure 7). Compared to the ATP
content measured following isoosmotic treatment, there was no change in ATP content
following hypoosmotic exposure or with any of the pharmacological treatments. Thus,
the osmotic treatments with PBS generally decreased the viability of cell cultures
measured 24 h or later, however, pharmacological treatments under these conditions did
not further augment this effect.
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Figure 7. ATP Content was Unchanged with Swelling or Pharmacological
Treatments. Neuron cultures were incubated under isoosmotic conditions or
hypoosmotic conditions for 30 min. Pharmacological activators or inhibitors of tyrosine
kinases or PKC were added to some cultures exposed to isoosmotic conditions. Cultures
were then returned to media and allowed to recover for 24 h. Other cultures were
prepared for ATP analysis without treatment. Isoosmotic and hypoosmotic treatments
caused a significant decrease in ATP content compared to untreated cultures. No
difference in ATP was seen with any treatment compared to cultures in isoosmotic
conditions. Values are mean ± SEM of at least 6 independent determinations. Data were
analyzed using a one-way ANOVA followed by Tukey’s HSD test for post hoc
comparisons (*p < 0.05).

To further assess the viability of neuron cultures following the 1 µM PMA
treatment used in these experiments, we used Annexin V immunostaining to observe any
possible apoptotic process. Annexin V is a phospholipid-binding protein that has a high
affinity for phosphatidylserine, a phospholipid that is translocated from the inner leaflet
to the outer leaflet of the plasma membrane in apoptotic cells. Neurons grown on glass
coverslips were treated under isoosmotic conditions with or without 1 µM PMA for 30
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min. Coverslips were returned to media and allowed to recover for 24 h after which cells
were immunostained with 4’,6’-diamidino-2-phenylindole (DAPI) and Annexin V. As
seen in Figure 8, Annexin V staining was unchanged compared with cells left untreated.
Thus, PMA at this concentration did not cause an increase in apoptosis.

Figure 8. Apoptosis did not Increase with Activation of PKC. Neurons grown on glass
coverslips were treated under isoosmotic conditions with or without 1 µM PMA for 30
min then allowed to recover in media for 24 h. Following recovery, cells were stained
with DAPI and Annexin V to assess cell viability. Cell viability was unaffected by
treatment with 1 µM PMA.

Subcellular Localization of the Neuronal Taurine Transporter Protein was Altered
by Hypoosmotic Swelling. Subcellular fractionation was performed on neuronal
cultures maintained in isoosmotic or hypoosmotic conditions for 30 min (Figures 9A and
9B, respectively). In isoosmotic conditions western blotting of each fraction and the raw
lysate obtained prior to fractionation showed that TauT was primarily found in the
membrane/particulate and cytosolic fractions at ~98 kDa. In contrast, after hypoosmotic
treatment TauT staining was observed in the nuclear fraction and not in the
membrane/particulate or cytosolic fractions. In addition, following hypoosmotic

58

exposure, the molecular weight of TauT in the nuclear fraction was ~73 kDa, a size more
characteristic of its calculated molecular weight (Smith, Borden et al. 1992). Thus,
western blots showed that the molecular weight of the TauT protein was reduced in
osmotically swollen neurons concomitant with its redistribution from the neuronal cell
membrane fraction to the nuclear fraction.

59

Figure 9. Subcellular Localization of the Neuronal Taurine Transporter Protein was
Altered by Hypoosmotic Swelling. Subcellular fractionation was performed with
neuronal cultures maintained in isoosmotic (A) or hypoosmotic (B) conditions for 30
min. Under isoosmotic conditions, TauT was primarily found in the cytosol and cell
membrane fractions at ~98 kDa. After hypoosmotic treatment TauT was not found in the
membrane or cytosolic fractions while relatively stronger TauT staining was observed in
the nuclear fraction. In addition, following hypoosmotic exposure, the molecular weight
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of TauT in the nuclear fraction decreased to ~73 kDa. RL - Raw Lysate Cyt - Cytosol,
Mem - Membrane, Nuc - Nucleus, Csk - Cytoskeleton.

TauT resolution on western blots was not consistently adequate to accurately
measure the intensity of immunoreactive bands. For this reason, dot blots were chosen for
the remaining analyses and statistical data represent only these dot blot experiments.
Band densities from dot blots were background subtracted and normalized to that
measured in raw cell lysate for each fraction. As with the western blots, dot blots showed
that under isoosmotic conditions, TauT was located mostly in the cytosolic and
membrane/particulate fractions (Figure 10). TauT band density for the cytosolic,
membrane/particulate, nuclear, and cytoskeletal fractions was 83% ± 8.2%, 13% ± 3.7% ,
6% ± 2.1%, and undetectable, respectively, under isoosmotic conditions. When cells were
exposed to hypoosmotic conditions TauT band density significantly decreased in the
membrane/particulate fraction (by 98%) relative to TauT in the membrane/particulate
fraction under isoosmotic conditions (p < 0.05) and tended to increase (by 33%) in the
nuclear fraction (Figure 11).
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Figure 10. Representative Dot Blot of Primary Neuron Cultures Treated Under
Isoosmotic and Hypoosmotic Conditions. Bovine seruma albumin (BSA) was used as a
negative control and Tau1 antigen served as a positive control. Raw cell lysate (untreated
lysate) was loaded in dilutions to assess linearity of band density relative to protein
loading. D1, D1/2, and D1/4 = full, half, and quarter dilutions of raw cell lysate.
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Figure 11. Membrane/Particulate TauT Decreased with Cell Swelling in Neurons.
Band densities from dot blots were background subtracted and normalized to raw cell
lysate for each fraction. TauT density significantly decreased in the membrane/particulate
fraction and tended to increase in the nuclear fraction following hypoosmotic exposure
(green bar) compared to isoosmotic exposure (red bar). Values are mean ± SEM of at
least 6 independent determinations. Data were analyzed using a one-way ANOVA
followed by Tukey’s HSD test for post hoc comparisons or the Kruskal-Wallis Test
where appropriate. (*p < 0.05).

Purity of Subcellular Fractions. Lysates from neuronal cells treated under isoosmotic
conditions for 30 min were fractionated. A dot blot was loaded with equal amounts of
protein for each fraction and the membrane probed for markers of each cellular fraction
(Figure 12). Cytosolic proteins were identified with an antibody to heat shock protein 70
(Hsp70); the membrane/particulate proteins with an antibody to the Na+/K+-ATPase;
nuclear fraction proteins with an antibody to Histone H1; and cytoskeletal proteins with
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an antibody to β-actin. The results indicated that the majority of Na+/K+-ATPase and
Histone H1 were in the membrane/particulate and the nuclear fractions, respectively. The
cytosolic and cytoskeletal fractions contained various amounts of all of the proteins
examined.

Figure 12. Subcellular Fraction Purity. Neuron cell lysate treated under isoosmotic
conditions for 30 min was fractionated. The majority of the Na+/K+-ATPase and Histone
H1 were found in the membrane and nuclear fractions, respectively. The cytosolic and
cytoskeletal fractions contained a variable mixture of each of the examined proteins.

Biotinylation of Neuronal TauT. The membrane/particulate fraction obtained in the
subcellular fractionation experiments may not represent strictly plasma membrane
protein. Other cellular membranes may also be included, i.e. endosomal membranes,
nuclear membranes, etc. Therefore, we used cell surface biotinylation to identify only cell
surface proteins, since sulfo-NHS-SS-biotin is impermeable to the plasma membrane.
Upon western blotting for TauT, two immunoreactive bands were present at 75 kDa and
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50 kDa for cells treated under isoosmotic or hypoosmotic conditions. Both the high and
low molecular weight band densities were decreased relative to the raw lysate by preabsorption of the TauT antibody with its peptide antigen, Tau1, by 21% and 43% in
isoosmotic conditions and 44% and 37% in hypoosmotic conditions for the 75 kDa and
50 kDa bands, respectively, suggesting that both bands represented the taurine transporter
(Figure 13)2. Thus, each band was measured separately in all experiments. In both cases,
hypoosmotic exposure caused a significant decrease (67% for the 50 kDa band and 70%
for the 75 kDa band) in plasma membrane TauT (p < 0.05) (Figure 14). Taken together
with the subcellular fractionation studies, these results indicate that osmotic swelling
decreased the amount of TauT on the neuronal plasma membrane.

Figure 13. Both the High and Low Molecular Weight Bands Present in Neurons
with Biotinylation were Pre-absorbed with the Antigen to TauT. TauT was
biotinylated in neuronal cell lysates treated under isoosmotic or hypoosmotic conditions.
Upon immunoblotting with an antibody to TauT both a high and a low molecular weight
band were present. Both of these bands decreased in intensity when the TauT antibody
was pre-absorbed with it’s peptide antigen, Tau1, prior to immunostaining. Band
densities were background subtracted and normalization to raw cell lysate.
MW=molecular weight standard ladder, RL=raw cell lysate, and Biotin=biotinylated
TauT.

2

Note that the immunoblots shown display TauT bands at ~102 kDa and ~60 kDa, whereas the data
analysis indicates a ~75 kDa and ~ 50 kDa band. This discrepancy is purely a result of an average distance
calculated from all western blots used for data analysis. Please see the section describing MW changes in
TauT for further information regarding this discrepancy.
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Figure 14. Plasma Membrane TauT Decreased with Cell Swelling in Neurons. Band
densities from western blots were background subtracted and normalized to the total
TauT present in the raw cell lysate. A 75 kDa and 50 kDa immunoreactive band were
detected on western blots (A). The percent of biotinylated TauT significantly decreased
following hypoosmotic treatment (green bar) as compared to isoosmotic treatment (red
bar) (B). Values are mean ± SEM of 4 independent determinations. Data were analyzed
using a one-way ANOVA followed by Tukey’s HSD test for post hoc comparisons. For
the 50 kDa band, we used a log transformation of the average % biotinylated TauT (*p <
0.05). MW=molecular weight standard ladder, Biotin=biotinylated TauT

TauT Interaction with Actin. We used mass spectrometry in an attempt to identify the
portion of TauT that was present in the 50 kDa band. However, rather than TauT, the 50
kDa band was identified to be representative of actin (see results page 87). This led us to
question whether a small immunoreactive fragment of the taurine transporter may be
bound to the actin cytoskeleton. To assess this interaction, TauT and actin were
immunoprecipitated from separate aliquots of neuronal cell lysate. Immunoblotting for
actin in the TauT immunoprecipitate and immunoblotting for TauT in the actin
immunoprecipitate was performed. In both cases 75 kDa and 50 kDa bands were
identified on the immunoblots (Figure 15). Multiple other bands in the raw cell lysate on
the immunoblot stained for actin might indicate non-specific binding or actin breakdown
products. Nonetheless, these findings suggest a possible interaction between TauT and
the actin cytoskeleton. Further research is needed to clarify this interaction. Also, because
of the uncertainty regarding the molecular identity of the 50 kDa band, only the 75 kDa
band was quantified in further experiments.
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Figure 15. TauT Interacted with the Actin Cytoskeleton. Actin was
immunoprecipitated from neuronal cell lysate and immunoblotted for reactivity to TauT
(A). TauT was immunoprecipitated from the same cell lysate and immunoblotted for
reactivity to Actin (B). As shown, both a 75 kDa TauT band and a 50 kDa actin band
were present in both immunoblots. RL-Raw Lysate, IP-Immunoprecipitated TauT
Control

Signaling Pathways Responsible for Reduction in Cell Surface TauT. Subcellular
fractionation and cell surface biotinylation were further used to assess whether a tyrosine
kinase signaling pathway or a PKC signaling pathway was responsible for the reduction
in plasma membrane TauT seen with hypoosmotic swelling. Dot blots were used for all
subcellular fractionation experiments whereas western blots were used for all
biotinylation experiments.
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For subcellular fractionation studies as mentioned previously, hypoosmotic
treatment caused a significant decrease (98%) in TauT in the membrane/particulate
fraction (p < 0.05) (Table 1). Inhibition of tyrosine kinases by addition of 100 µM
genistein under hypoosmotic conditions reversed the decrease in membrane/particulate
fraction TauT. Inhibition of PKC by treatment with 2.5 µM chelerythrine under
hypoosmotic conditions also significantly reversed the decrease in membrane/particulate
TauT that was seen with cell swelling (p < 0.05). No other pharmacological treatments
significantly affected the localization of TauT.

Table 1. Inhibition of Tyrosine Kinases Prevented TauT Internalization Following
Cell Swelling. Neurons were treated under isoosmotic or hypoosmotic conditions with or
without activators or inhibitors of tyrosine kinases or PKC. Band densities from western
blots were background subtracted and normalized to the band density measured in the
raw cell lysate. TauT significantly decreased in the membrane/particulate fraction under
hypoosmotic conditions. This was reversed upon inhibition of PKC under swelling
conditions. Values (%) are mean ± SEM of at least 4 independent determinations. Data
were analyzed using a one-way ANOVA followed by Tukey’s HSD test for post hoc
comparisons or the Kruskal-Wallis Test where appropriate. (*p < 0.05).
In biotinylation experiments, hypoosmotic cell swelling significantly decreased
biotinylated TauT (from 23% to 7% relative to raw lysate band density) (Figure 16).
Inhibition of tyrosine kinases by 100 µM genistein under hypoosmotic conditions
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significantly reversed the decrease in plasma membrane TauT. Activation of PKC with 1
µM PMA under isoosmotic conditions had no effect on TauT localization.

Figure 16. TauT Internalization was Prevented by Inhibition of Tyrosine Kinases in
Neurons. Band densities from western blots were background subtracted and normalized
to the total TauT present in the raw cell lysate. As compared with isoosmotic treatment
(red bar) the percent of biotinylated TauT significantly decreased following hypoosmotic
treatment (green bar). This decrease was prevented upon treatment with 100 µM
genistein (purple bar), a tyrosine kinase inhibitor. 1 µM PMA (blue bar) had no effect on
TauT localization. Values are mean ± SEM of 4 independent determinations. Data were
analyzed using a one-way ANOVA followed by Tukey’s HSD test for post hoc
comparisons (*p < 0.05).

Osmotic Cell Swelling Caused an Increase in Phosphorylated Tyrosine Residues on
TauT in Neurons. TauT was immunoprecipitated from neuronal cell lysate after a 30
min treatment in isoosmotic or hypoosmotic conditions in the presence or absence of
activators or inhibitors of tyrosine kinases and PKC. The immunoprecipitated protein was
analyzed using SDS-PAGE followed by western blotting with antibodies specific for
phosphorylated serine, threonine, and tyrosine residues. Two separate bands, both
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immunoreactive with the TauT antibody, were present on western blots at approximately
75 kDa and 50 kDa (Figure 17). Based on the mass spectrometric identification of 50 kDa
bands in immunoblots as actin described above, only the 75 kDa band was used for data
analysis. Following hypoosmotic exposure the band density at 75 kDa for phosphorylated
tyrosine residues significantly increased by 25% (p < 0.05) (Figure 18). This increase in
phospho-tyrosine band density at 75 kDa was significantly reversed by 34% when a
tyrosine kinase inhibitor was added under hypoosmotic conditions. The band densities for
phosphorylated serine and threonine residues were of the same magnitude on TauT under
both isoosmotic and hypoosmotic conditions and with all pharmacological treatments.
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Figure 17. Representative Western Blot of Immunoprecipitated Neuronal TauT
Stained with Anti-Phospho Protein Antibodies. TauT was immunoprecipitated from
neuronal cell lysate under isoosmotic (A) and hypoosmotic (B) conditions and western
blots were immunostained with phospho-specific antibodies. RL-Raw Lysate, IPImmunoprecipitated TauT
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Figure 18. Phosphorylation of Tyrosine Residues on TauT Increased with Cell
Swelling in Neurons. Neuronal TauT was immunoprecipitated and assessed for changes
in phosphorylation patterns following cell swelling. Band densities were background
subtracted and normalized to total immunoprecipitated TauT. As compared with
isoosmotic treatment (red bar), staining of phosphorylated tyrosine residues significantly
increased following hypoosmotic exposure (green bar). This increase was prevented by
treatment with 100 µM genistein (purple bar), a tyrosine kinase inhibitor. PMA (1 µM)
(blue bar) had no effect on TauT phosphorylation. Values are mean ± SEM of at least 4
independent determinations. Data were analyzed using a one-way ANOVA followed by
Tukey’s HSD test for post hoc comparisons or the Kruskal-Wallis Test where appropriate
(*p < 0.05).

Mass Spectrometric Identification of Proteins in C6 cells. To develop protocols for the
identification of proteins using an in-gel tryptic digest and MALDI-TOF/TOF mass
spectrometry, C6 glioma cells were exposed to isoosmotic conditions for 30 min and then
lysed. The lysate was concentrated and duplicate 1D SDS-PAGE gels used to separate
proteins. Immunoblotting was performed on one gel to identify the position of TauT.
Bands representing TauT were cut from the other SDS-PAGE gel and an in-gel tryptic
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digest was performed (Figure 19). Digested peptides were desalted using ZipTips® and
spotted on a MTP 384 brushed-steel target plate for MALDI-TOF/TOF analysis. Peaks
from the mass spectrum were selected and fragmented into ions. The amino acid
sequences resulting from these fragmented ions were searched against multiple protein
databases using the WSU-PAL Mascot server. Probability based scores indicated
significant hits identifying proteins present in the digested samples. Hsp90β was
identified in a ~75 kDa band and albumin was identified in a ~50 kDa band.

Figure 19. Mass Spectrometric Identification of Proteins in C6 cells. C6 cell lysate
was separated by 1D SDS-PAGE (A). Bands corresponding to TauT in the immunoblot
(B) were cut out of the gel (white boxes) and digested. Tryptic digests were spotted and
analyzed with MALD-TOF/TOF MS. HSP90β and albumin were identified in these cells.
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Mass Spectrometric Identification of Proteins in 1321N1 cells, Neurons, and
Astrocytes. To further analyze phosphorylation sites of TauT during hypoosmotic cell
swelling, we used mass spectrometry to identify and sequence the TauT protein. We
began by using 1-dimensional gel electrophoresis and an in-gel tryptic digest of protein
bands of interest followed by MALDI-TOF/TOF mass spectrometry. Although we were
able to identify multiple parent ion peaks in the 75 kDa range, these peaks were not
successfully fragmented and were unable to yield any amino acid sequences with
significant homology to proteins searched in the MASCOT, NCBInr, or SwissProT
databases. Because TauT is in low concentration relative to other proteins in the cell, we
realized that a more sensitive method was necessary to isolate TauT. This led us to use 2dimensional gel electrophoresis to separate the proteins in our sample by both molecular
weight and isoelectric point. However, identifying TauT using this technique was also
uncertain because of a discrepancy in reported pI values. Liu and Lopez-Corcuera et al.
(1992) report an acidic pI for TauT of 5.98. In contrast, the SequenceEditor program used
at the WSU-PALS laboratory estimated TauT pI to be 7.1. Thus, to increase our chances
at identifying the taurine transporter protein, we conducted a comprehensive proteome
analysis of 1321N1 (astrocytoma), neuron, and astrocyte cell lysates using 2D gel
electrophoresis (Figures 20-22). Proteins digested from a 2D gel of Escherichia coli were
used as controls (Figure 23). Additionally, we immunoprecipitated TauT from cell lysates
and used 1D gel electrophoresis in an effort to isolate a single protein at 75 kDa (Figures
24-25).
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Figure 24 Immunoprecipitated Neuronal TauT on 1D SDS-PAGE. Raw neuronal cell
lysate or immunoprecipitated lysate was separated on a 10% polyacrylamide pre-cast gel
then stained with GelCode Blue. Following an in-gel tryptic digest of the gel bands
indicated, peptides were analyzed by MALDI TOF/TOF MS. The identities of the
proteins indicated in white are also shown in Table 2. The remaining gel bands were
unable to be identified.
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Figure 25. Immunoprecipitated Astrocytic TauT on 1D SDS-PAGE. Raw astrocytic
lysate or immunoprecipitated lysate was separated on a 10% polyacrylamide pre-cast gel
then stained with GelCode Blue. Following an in-gel tryptic digest, peptides were
analyzed by MALDI TOF/TOF MS. The identities of the proteins indicated in white are
also shown in Table 2.
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In total, 15 different proteins were identified using either 1D or 2D gel
electrophoresis followed by MALDI-TOF/TOF-MS in neurons, 9 proteins were identified
in astrocytes, 4 proteins were identified in 1321N1 cells, 2 proteins were identified in C6
cells, and 3 proteins were identified in an Escherichia coli control sample (Table 2).
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Table 2. Proteins Identified by MALDI-TOF/TOF MS. The identity of the proteins
from neuronal, astrocytic, 1321N1 cell lysate, C6 cell lysate, or the E. coli control sample
were analyzed by MALDI TOF/TOF MS. All peptide mass fingerprinting, CID and LIFT
data were analyzed by searching the MASCOT server at the WSU-PAL. The data were
searched against the Mascot, Swiss Proteomics, or NCBInr database. All proteins listed
in the table had scores indicating significant sequence homology. Protein scores are
derived from ion scores (-10*Log(P), where P is the probability that the observed match
is a random event). Individual ion scores presented here indicated identity or extensive
homology to the protein listed (p < 0.05).

Figure 26 shows the peptide mass fingerprint, the MS/MS spectra, the sequence
data, and the probability based scoring for the 50 kDa band found on immunoblots from
neurons. Automated MALDI-TOF/TOF-MS produced a peptide mass fingerprint in
which 4 parent peaks (976, 1132, 1499, and 1790) were identified as having sufficient
resolution to be successfully fragmented (Figure 26A). Fragmentation of these 4 parent
ions produced amino acid sequences that displayed significant identity to N-terminal, Cterminal, and internal portions of actin (Figures 26B-E) with a probability score of 221
(all scores > 39 were considered significant) (Figures 26F-G).
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Figure 26. MALDI TOF/TOF Identification of Actin in Neurons. Mass spectrum for a
50 kDa protein sample from the immunoprecipitation of neuronal cell lysate (A).
Fragmentation of parent peaks 976 (B),1132 (C), 1499 (D), and 1790 (E) revealed amino
acid sequences with significant homology to actin (F, G). Protein scores are derived from
ion scores (-10*Log(P), where P is the probability that the observed match is a random
event). Individual ion scores > 39 indicate identity or extensive homology (p < 0.05).

Figure 27 shows the peptide mass fingerprint, the MS/MS spectra, the sequence
data, and the probability based scoring for the 50 kDa band found on immunoblots from
astrocytes. Automated MALDI-TOF/TOF-MS produced a peptide mass fingerprint in
which 4 parent peaks (976, 1132, 1515, and 1790) were identified as having sufficient
resolution to be successfully fragmented (Figure 27A). Fragmentation of these 4 parent
ions produced amino acid sequences that displayed significant identity to N-terminal and
multiple internal portions of actin (Figures 27B-E) with a probability score of 285 (all
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scores > 55 were considered significant) (Figure 27F-G). All other mass spectra for
identified proteins are located in the appendix of this document.
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Figure 27. MALDI TOF/TOF Identification of Actin in Astrocytes. Mass spectrum
for a protein sample from the immunoprecipitation of astrocyte cell lysate (A).
Fragmentation of parent peaks 976 (B),1132 (C),1515 (D), and 1790 (E) revealed amino
acid sequences with significant homology to actin (F, G). Protein scores were derived
from ion scores (-10*Log(P), where P is the probability that the observed match is a
random event). Individual ion scores > 55 indicated identity or extensive homology (p <
0.05).
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Identification of the Taurine Transporter Protein in Hippocampal Astrocytes.
Immunoblotting was used to identify the taurine transporter protein in primary
hippocampal astrocytes (Figure 28). Western blot analysis showed a TauT band at ~53
kDa.

Figure 28. Identification of the Taurine Transporter Protein in Hippocampal
Astrocytes. TauT is present in hippocampal astrocytes. Under baseline (no treatment)
conditions, a band for TauT was found at ~53 kDa. Lanes 1-6 are duplicate samples
loaded at various concentrations of protein. Lane 7 is the molecular weight standard
ladder.

Since the molecular weight of the TauT protein in this band is less than the 72-75
kDa molecular weight calculated from the amino acid sequence of TauT, we considered
that the protein might have been cleaved by proteases that were not inhibited during cell
lysis and that the band might represent a C-terminal portion of the TauT protein to which
our antibody was manufactured. To examine this, 10 μM and 30 μM 4-(2-Aminoethyl)
benzenesulfonyl fluoride hydrochloride (AEBSF), an irreversible serine protease
inhibitor, was added to the normal protease inhibitor cocktail during cell lysis. The results
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in Figure 29 show that the treatments caused a shift in TauT molecular weight toward
normal (64 kDa and 61 kDa with10 µM and 30 µM AEBSF, respectively). This
suggested that in the absence of AEBSF, TauT is cleaved resulting in the 53 kDa band
indicative of a C-terminal peptide portion recognized by our TauT antibody.
Additionally, since the molecular weight did not increase to the expected 72 kDa there
may be other proteases that are not inhibited during our cell lysis procedure.

Figure 29. Additional Protease Inhibitors Increased TauT Molecular Weight
Toward its Calculated Value. Serine proteases in the astrocyte cell lysate were inhibited
with 10 μM (A) or 30 µM AEBSF (B). For both concentrations, a band for TauT was
found at ~63 kDa. This is greater than the MW of the band seen for TauT when AEBSF
is not present, but is less than the ~72 kDa band for TauT calculated from the amino acid
sequence.

TauT also was demonstrated in hippocampal astrocyte cultures by
immunostaining. Cells on glass coverslips were treated under isoosmotic or hypoosmotic
conditions in the presence or absence of pharmacological agents (described previously in
this document) for 30 min then fixed, blocked, and incubated with an antibody to the
taurine transporter (1:375). FITC-conjugated goat anti-rabbit immunoglobulin (1:100)
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was used as the secondary antibody. Immunostaining revealed strong TauT staining in
cell cultures. As in neurons, TauT staining was present throughout the entire cell
including the cytosol and to the ends of the extended cell processes (Figure 30).

Figure 30. Immunofluorescence of TauT in Hippocampal Astrocytes. Cells shown in
(A) were treated under hypoosmotic conditions and cells shown in (B) were treated under
isoosmotic conditions in the presence of 100 µM genistein for 30 min then fixed,
blocked, and incubated with anti-TauT antibody. Immunostaining reveals strong TauT
staining throughout the entire cell.
Upon preparation of the samples using subcellular fractionation, cell surface
biotinylation, and immunoprecipitation, TauT bands were identified at ~72-75 kDa and
~50 kDa in the raw cell lysate similar to results observed in neurons (Figure 31). Both the
high and the low molecular weight band densities in these western blots were decreased
upon pre-absorption of the TauT antibody with its peptide antigen, Tau1. The high
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molecular weight band density was decreased by 58% and the low molecular weight band
density was decreased by 5%.

Figure 31. Both the High and Low Molecular Weight Bands Present in Astrocytes
with Biotinylation were Pre-absorbed with the Antigen to TauT. TauT was
biotinylated in astrocytic cell lysates treated under isoosmotic conditions. Upon
immunoblotting with an antibody toward TauT both a high and a low molecular weight
band were present (A). Both of these bands decreased in intensity when the TauT
antibody was pre-absorbed with it’s peptide antigen, Tau1, prior to immunostaining (B).
MW=molecular weight standard ladder, RL=raw cell lysate, and Biotin=biotinylated
TauT.

Viability of Astrocytic Cell Cultures Following Pharmacological Treatments. To
assess whether the pharmacological treatments used in these experiments affected cell
viability, a luciferin-luciferase bioluminescence assay was performed for quantitative
determination of astrocytic ATP. Pharmacological activators and inhibitors of tyrosine
kinases and PKC were incubated with the cell cultures under isoosmotic conditions for 30
min. The cells were returned to media and allowed to recover for 24 h. Compared to
isoosmotic treatment, there was no change in ATP content with the pharmacological
treatments (Figure 32).
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Figure 32. Viability of Astrocyte Cell Cultures Following Pharmacological
Treatment. Astrocyte cultures were incubated under isoosmotic conditions with
pharmacological activators or inhibitors of tyrosine kinases or PKC for 30 min then
returned to media and allowed to recover for 24 h. No difference in ATP was seen
compared to untreated cells with isoosmotic or hypoosmotic treatment. There also was no
difference in ATP content when cells were treated with the various drugs. Values are
mean ± SEM of at least 6 independent determinations. Data were analyzed using a oneway ANOVA.

Subcellular Localization of the Astrocytic Taurine Transporter Protein was not
Altered by Hypoosmotic Swelling. Subcellular fractionation was performed with
astrocyte cell cultures maintained in isoosmotic or hypoosmotic conditions for 30 min.
Equal protein from each fraction was loaded onto a dot blot apparatus and assessed using
ECL (Figure 33). The Tau1 peptide was used as a positive control and BSA was used as a
negative control. Densities of Tau1 bands were saturated while spots with BSA indicated
no staining. Also, raw cell lysate was loaded in dilutions of 100 µg, 50 µg, and 25 µg.
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Figure 33. Representative Dot Blot of Primary Astrocyte Cultures Treated Under
Isoosmotic and Hypoosmotic Conditions. Cells were fractionated and loaded into
different wells. The majority of peptide in each treatment was found in the cytosolic
fraction for each osmotic treatment. Relatively little TauT protein was found in the
membrane/particulate, nuclear, or cytoskeletal fractions. Tau1 was a positive control and
BSA was a negative control.

After both isoosmotic and hypoosmotic treatments, TauT was primarily found in
the cytosolic fraction (83.65% in isoosmotic and 88.22% in hypoosmotic conditions)
(Figure 34). Analysis of band densities also indicated a small amount of TauT in the other
fractions. Under isoosmotic conditions, TauT density in the membrane, nuclear, and
cytoskeletal fractions was 4%, 7%, and 5%, respectively. Under hypoosmotic conditions,
TauT density in the membrane, nuclear, and cytoskeletal fractions was 3%, 3%, and 6%,
respectively. These values were not significantly different from those measured in
isoosmotic conditions.
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Figure 34. Percentage of TauT in Astrocytic Cell Fractions. TauT distribution was not
altered in swollen astrocytes. Band densities from dot blots were background subtracted
and normalized to the band density of the raw cell lysate for each fraction. TauT band
density was not significantly different from that measured in isoosmotic conditions (red
bar) for any fraction following hypoosmotic treatment (green bar). Values are mean ±
SEM of at least 9 independent determinations. Data were analyzed using a one-way
ANOVA followed by Tukey’s HSD test for post hoc comparisons.

As with subcellular fractionation in neurons, the membrane/particulate fraction in
the subcellular fractionation experiments in astrocytes may contain proteins from
membranes other than the plasma membrane. Thus, cell surface biotinylation was
performed to more accurately determine changes in plasma membrane expression of
TauT. Upon western blotting to determine the quantity of biotinylated TauT,
immunoreactive bands were present at ~75 kDa and ~50 kDa (Figure 35).
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Figure 35. Biotinylation of Astrocytic TauT. Astrocytes were treated under iso- (A) or
hypo-osmotic (B) conditions for 30 min then biotinylated and immunoblotted for TauT.
Two immunoreactive bands were present at ~75 kDa and ~50 kDa. MW=molecular
weight standard ladder, Biotin=biotinylated TauT

Since both band densities were decreased by pre-absorption of the TauT antibody
with its peptide antigen, (see Figure 31), each band was measured separately in these
experiments. The background corrected density for both immunoreactive bands was
unchanged following hypoosmotic exposure compared to that measured in isoosmotic
conditions (Table 3). Taken together, subcellular fractionation and cell surface
biotinylation studies demonstrated osmotic swelling does not change the amount of TauT
on the plasma membrane in astrocytes.
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Table 3. Plasma Membrane TauT was Unchanged with Cell Swelling in Astrocytes.
Band densities from western blots were background subtracted and normalized to the
total TauT present in the raw cell lysate. The percent of biotinylated TauT following
hypoosmotic treatment was not significantly different from that measured in isoosmotic
conditions. Values are mean ± SEM of 4 independent determinations. Data were analyzed
using a one-way ANOVA followed by Tukey’s HSD test for post hoc comparisons. For
the 50 kDa band, we used a log transformation of the average % biotinylated TauT.

Mass spectrometric Analysis of the 50 kDa Band from Astrocytes. Similar to
neuronal cells, mass spectrometric analysis of the 50 kDa band in astrocytes identified it
to be representative of actin (see Figure 27). To assess a possible interaction between
TauT and actin in astrocytes, TauT and actin were immunoprecipitated from separate
aliquots of astrocytic cell lysate. Then immunoblots were probed for actin in the TauT
immunoprecipitate and for TauT in the actin immunoprecipitate. As with the neurons, a
75 kDa band and a 50 kDa band were identified in astrocyte western blots for both
immunoprecipitations in both cases (Figure 36). This suggested an interaction between
TauT and the actin cytoskeleton. Further research is needed to confirm this interaction
and for this reason, only the 75 kDa band was quantified in further experiments.
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Figure 36. TauT Interacted with the Actin Cytoskeleton. Actin was
immunoprecipitated from astrocytic cell lysate and immunoblotted for reactivity to TauT
(A). TauT was immunoprecipitated from the same cell lysate and immunoblotted for
reactivity to actin (B). As shown, both a 75 kDa TauT band and a 50 kDa actin band were
present in both immunoblots.

Cell Signaling Pathways Involved in TauT Localization in Astrocytes. To determine
whether phosphorylation of astrocytic TauT was involved in its regulation, astrocytes
cultures were treated for 30 min with 1 μM PMA, an activator of PKC, or 1 mM
orthovanadate, an inhibitor of tyrosine phosphatases, in isoosmotic conditions, or with
2.5 µM chelerythrine, an inhibitor of PKC, in hypoosmotic conditions. Subcellular
fractions were prepared and TauT presence in each fraction was quantitatively analyzed
by western blot. As shown in Table 4, the density of the TauT bands in the cytosol,
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membrane/particulate, nuclear, and cytoskeletal fractions for each treatment were not
significantly different from control cultures treated with isoosmotic or hypoosmotic
conditions without the activator or inhibitor of PKC or inhibitor of tyrosine phosphatases.

Table 4. Percentage of TauT in Astrocytic Cell Fractions Following
Pharmacological Treatments. TauT distribution was not altered in swollen astrocytes.
Band densities from dot blots were background subtracted and normalized to the band
density of the raw cell lysate for each fraction. TauT band density was not significantly
different from that measured in isoosmotic conditions for any fraction following any
treatment. Values (%) are mean ± SEM of at least 6 independent determinations. Data
were analyzed using a one-way ANOVA followed by Tukey’s HSD test for post hoc
comparisons.

Since we would have expected to see a decrease in membrane TauT with
activation of PKC, we considered that our subcellular fractionation assay was not
accurately measuring plasma membrane TauT. The membrane fraction may contain
membranes from other intracellular structures, thus cell surface biotinylation was
performed to assess the presence of TauT specifically on plasma membrane. Activation
of PKC by treatment with 1 µM PMA under isoosmotic conditions caused a significant
decrease in biotinylated (plasma membrane) TauT by 84% compared to control cultures
(p < 0.05) (Figure 37).
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Figure 37. Plasma Membrane TauT Decreased with PKC Activation in Astrocytes.
Band densities from western blots were background subtracted and normalized to the
total TauT present in the raw cell lysate. As compared to isoosmotic conditions (red bar),
a significant decrease was found upon treatment with 1 µM PMA (blue bar).
Hypoosmotic treatment (green bar) had no effect on TauT localization. Values are mean
± SEM of 4 independent determinations. Data were analyzed using a one-way ANOVA
followed by Tukey’s HSD test for post hoc comparisons (*p < 0.05).

Osmotic Cell Swelling did not Change Phosphorylated Serine, Threonine, or
Tyrosine Residues on TauT in Astrocytes. TauT was immunoprecipitated from
astrocytic cell lysates after a 30 min treatment in isoosmotic or hypoosmotic conditions in
the presence or absence of an activator of PKC. The immunoprecipitated protein was
analyzed using 1D SDS-PAGE followed by western blotting. Membranes were
immunostained with antibodies specific for phosphorylated serine, threonine, and
tyrosine residues (Figure 38). Two bands were present on western blots at approximately
75 kDa and 50 kDa.
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Figure 38. Representative Western Blot of Immunoprecipitated Astrocytic TauT
Stained with Anti-Phospho Protein Antibodies. TauT was immunoprecipitated from
neuronal cell lysate under isoosmotic and hypoosmotic conditions and western blots were
stained with antibodies specific for phospho-serine and phospho-threonine (A) and
phospho-tyrosine (B).

Following hypoosmotic exposure, densities of the 75 kDa phosphorylated serine,
threonine, and tyrosine bands were not significantly different from that measured in
control cultures (Figure 39). However, a significant increase in the densities measured for
phosphorylated serine and threonine residues (by 64% and 72%, respectively) was seen
upon activation of PKC under isoosmotic conditions (p < 0.05).
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Figure 39. Phosphorylation of Serine and Threonine Residues on TauT Increased
with PKC Activation in Astrocytes. Astrocytic TauT was immunoprecipitated and
assessed for changes in phosphorylation patterns following cell swelling. Phosphorylated
serine and threonine residues significantly increased following PKC activation (blue bar).
Isoosmotic and hypoosmotic treatments are indicated in the red and green bars,
respectively. Values are mean ± SEM of 4 independent determinations. Data were
analyzed using a one-way ANOVA followed by Tukey’s HSD test for post hoc
comparisons (*p < 0.05).
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VI. DISCUSSION
SLC6 Membrane Transporters. Solute carriers (SLCs) constitute the second largest
family of membrane proteins (Hoglund, Nordstrom et al. 2011). The SLC6 transporters
are a member of this diverse family and, in the brain, include transporters for inhibitory
neurotransmitters, aminergic neurotransmitters, osmolytes, amino acids, and metabolic
compounds (Chen, Reith et al. 2004). Because these transporters are subject to regulation
by multiple signaling cascades, they are exciting targets for pharmacological
manipulation of various disease states (Chen, Reith et al. 2004). It was not until the early
1990s that the molecular characterization of one of the first identified SLC6 transporters,
GAT1, was begun (Guastella, Nelson et al. 1990; Chen, Reith et al. 2004). In the
following years, cloning enabled the discovery of many more of these transporters due to
their high degree of homology (Chen, Reith et al. 2004). Virtually all of the SLC6
transporters have since been shown to be functionally regulated by protein kinases,
protein-protein interactions, and redistribution to and from the plasma membrane and
intracellular compartments (Beckman and Quick 1998; Blakely and Bauman 2000; Chen,
Reith et al. 2004).

The Taurine Transporter. The taurine transporter (TauT) is a member of the SLC6
superfamily and is a transporter of the amino acid taurine. It is found in many tissues
throughout the body including the brain in both neurons and astrocytes, as well as in
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retina (Liu, Lopez-Corcuera et al. 1992; Smith, Borden et al. 1992; Loo, Hirsch et al.
1996; Vinnakota, Qian et al. 1997; Pow, Sullivan et al. 2002; Ando, Kubo et al. 2012).
Since TauT is known to be differentially regulated in response to osmotic imbalance in
these cells, we proposed to examine if cell signaling pathways were involved in its
regulation by phosphorylation and by redistribution between the cytosol and the plasma
membrane. The evidence presented in this dissertation has shown that phosphorylation
appears to play a role in TauT regulation and that TauT is differentially redistributed to
and from the plasma membrane in response to osmotic swelling and kinase signaling
pathways in neurons and astrocytes.

Identification of the Taurine Transporter Protein in Hippocampal Neurons and
Astrocytes. One of the first goals of this project was to identify and characterize TauT
expression in neurons and astrocytes. The molecular weight of rat brain TauT calculated
from its amino acid sequence is 72-75 kDa (Smith, Borden et al. 1992). However, we
observed that the molecular weight of the taurine transporter in normal cultured
hippocampal neurons was ~98 kDa by western blotting, significantly larger than the ~72
kDa value. In contrast, western blot results revealed the molecular weight of TauT in raw
cell lysate of normal cultured hippocampal astrocytes to be ~53 kDa, or considerably
smaller than the calculated molecular weight. It appeared that these relative molecular
weights were dependent on the preparation of the sample as TauT bands were identified
at ~72-75 kDa and ~50 kDa in both neurons and astrocytes following cell surface
biotinylation and immunoprecipitation. The identity of these bands as TauT was further
supported by studies in which the anti-TauT antibody was pre-absorbed with the TauT
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antigen peptide. Various studies from other laboratories utilizing a similar TauT antibody
also have reported molecular weights of TauT that differ from the calculated molecular
weight (Table 5) (Han, Budreau et al. 1996; Poulsen, Litman et al. 2002; Xu, Wagenfeld
et al. 2003; Iruloh, D'Souza et al. 2007).

Table 5. Molecular Weight of TauT Obtained From Different Cells and Tissues. The
TauT protein has been demonstrated at several molecular weights in different cell types.
This table represents a sampling of this variation in the literature and does not constitute
an exhaustive list of these molecular weight variations in all cells/tissues.
Despite the variability in molecular weight of TauT in various preparations, little
work has been conducted to determine the cause of this variability. The molecular
weights observed in this study suggested that TauT remains substantially glycosylated
following cell lysis in neurons and is subject to cleavage by proteases that are not blocked
by the standard cell lysis solution used for astrocytes. A critical function of astrocytes is
restructuring of damaged areas of the brain following various insults. Astrocytes not only
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limit the area of damage but also are involved in post-insult remodeling and recovery of
neural function (Hertz 1991; Wang and Bordey 2008; Sofroniew and Vinters 2010). The
enzymes responsible for these functions in astrocytes may have greater proteolytic
activity following cell lysis than enzymes released from the neurons. Thus, lysing
astrocytes could expose TauT to different degradative enzymes than in other cell types.
This could lead to the preparation-dependent shift in TauT apparent molecular weight
from 72 kDa to 50 kDa.
In astrocytes, we explored the possibility that TauT is cleaved by proteases that
remain uninhibited by our standard cell lysis protease inhibitor cocktail. Adding various
concentrations of an irreversible serine protease inhibitor to our standard lysis solution
increased the apparent TauT molecular weight on immunoblots. However, even the
highest concentration did not yield a TauT immunoreactive band at 75 kDa representative
of the calculated molecular weight of TauT. As mentioned previously, with various
assays, i.e. cell fractionation, cell surface biotinylation, immunoprecipitation, etc., for
both neurons and astrocytes, we also saw an immunoreactive band approximating the 75
kDa molecular weight of TauT. This strongly suggested that depending on the
preparation of cells, TauT is cleaved at various amino acid residue cleavage sites creating
a variety of TauT peptides of different molecular weights to which our C-terminal
antibody is able to bind. Due to the serine protease sensitive nature of these cleavages, we
propose that there may be lysine or arginine substitutions in the astrocyte derived TauT
that would explain some of the differential cleavage. It is possible that multiple isoforms
of TauT exist but have not yet been fully sequenced or identified in different cell
lines/tissues.
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To explore the glycosylation of TauT in neurons, we used enzymes specific for Nlinked and O-linked glycosylation. When both N- and O-linked enzymes were used, the
molecular weight of TauT decreased to ~58 kDa. Using only N-linked enzymes, the
molecular weight of TauT decreased to approximately ~81 kDa. These results suggested
that TauT was glycosylated by a variety of N-linked and O-linked carbohydrates and
could account for the apparent elevated molecular weight seen in the raw cell lysate.
These results also suggest that the presence of N- and O-linked carbohydrates provided
some level of protection from enzymatic degradation.
To our knowledge, our results provide the first evidence to explain the observed
variability in molecular weight of TauT in various preparations. Currently a rat brain
TauT has been sequenced, but there does not exist a sequence for the transporter from
different cell types in the same tissue such as neurons and astrocytes. Future studies of
the TauT protein would benefit from cloning of both the neuronal and astrocytic TauT
followed by DNA sequence analysis that would allow specific comparison and
characterization of each of these cell types with respect to TauT. Furthermore,
customized antibodies specifically immunoreactive to TauT in specific tissue/cell lines of
interest should be generated to provide better analysis by western blots,
immunocytochemistry and immunoprecipitation and to ensure that the antibody used is
accurately identifying TauT (Pow, Sullivan et al. 2002).

Summary of Results and Proposed Model of TauT Regulation in Neurons and
Astrocytes. Under isoosmotic conditions, TauT was primarily located in the cytosolic
and cell membrane fractions. When neurons were swollen under hypoosmotic conditions,
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the apparent molecular weight of the TauT protein on immunoblots was reduced from
~98 kDa to ~75 kDa while it was internalized from the neuronal cell membrane to the
nuclear fraction. The lower molecular weight observed in the swollen neurons was more
characteristic of the molecular weight calculated from the amino acid sequence of the
transporter. Since it was difficult to specifically isolate plasma membrane from other
cellular membranes, e.g., endosomal, nuclear, etc., cell surface biotinylation was
performed to confirm the results. As with cell fractionation, biotinylation experiments
showed that hypoosmotic treatment of neuron cultures caused a decrease in cell surface
TauT. In contrast to neurons, TauT remained on the plasma membrane in swollen
astrocytes. If this differential response in TauT localization occurred in the osmotically
swollen brain in vivo, it would allow continued accumulation of taurine together with
osmotically obliged water. This would limit the ability of astrocytes to regulate their cell
volume and would tend to render them swollen during osmotic brain edema.
The decrease in neuronal TauT in the membrane during hypoosmotic swelling
was reversed by inhibition of tyrosine kinases with 100 µM genistein. Also, cell
fractionation showed that inhibition of PKC with chelerythrine under swelling conditions
reversed the decrease in neuronal membrane TauT seen with cell swelling. Neuronal
TauT was unaffected by activation of PKC; however activation of PKC in astrocytes with
1 µM PMA decreased plasma membrane TauT. This is consistent with studies in a
placental cell line where activation of PKC caused a decrease in taurine uptake into the
cells and inhibition of PKC by staurosporine caused an increase in taurine uptake
(Kulanthaivel, Cool et al. 1991).
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To determine whether these two signaling pathways may cause direct
phosphorylation of TauT, the transporter was immunoprecipitated from neuronal and
astrocytic cell lysates treated under either isoosmotic or hypoosmotic conditions and
immunoblots of the precipitated proteins were probed with antibodies specific for
phosphorylated serine, threonine, and tyrosine residues. Results showed that TauT is
phosphorylated at serine, threonine, and tyrosine residues in unswollen cells (isoosmotic
conditions) in both neurons and astrocytes under isoosmotic conditions. With cell
swelling of neurons, phospho-tyrosine residues increased significantly on immunoblots.
This effect was blocked by inhibition of tyrosine kinases. Phosphorylation of TauT did
not change in swollen astrocytes; however PKC activation under isoosmotic conditions
increased phosphorylation of serine and threonine residues on TauT. These results
correlate with our studies on TauT localization and transport studies reported previously
(Jones, Miller et al. 1991; Beetsch and Olson 1996; Olson and Martinho 2006a; Olson
and Martinho 2006b) and suggest tyrosine phosphorylation is the signal by which TauT is
removed from the plasma membrane in swollen hippocampal neurons. Thus,
phosphorylation of TauT likely regulates the decrease in neuronal TauT functional
activity during cell swelling. Further, we speculate that phosphorylation of TauT is the
signal that causes the transporter to be internalized. In contrast, PKC must be responsible
for TauT trafficking and phosphorylation in astrocytes. We were unable to identify the
specific residues involved in the phosphorylation events in this study, i.e. Ser-21, Ser-25,
Ser-45, Ser-46, Ser-322, Tyr-320, and Thr-28, Thr-242, Thr-581, Thr-596, and Thr-603
which were potential candidates based on predictions to be presented later in this

116

document. For a summary of the changes affecting TauT in neurons and astrocytes, refer
to Table 6.

Table 6. Summary of TauT Regulation in Hippocampal Neurons and Astrocytes.
Cell swelling decreases TauT functional activity by activating tyrosine kinases which
phosphorylate TauT and cause its internalization from the plasma membrane to
intracellular compartments. Cell swelling does not affect astrocytic TauT, but PKC
activation causes phosphorylation and internalization of the protein concomitant with a
decrease in taurine transport. Asterisks indicate data from this study.
To integrate results in hippocampal neurons and astrocytes, we suggest a model in
which tyrosine kinases and PKC differentially act on TauT in both cell types (Figures 40
and 41). In neurons, swelling activates tyrosine kinases that increase tyrosine
phosphorylation on TauT. This in turn causes internalization of TauT from the plasma
membrane and a decrease in taurine uptake. In astrocytes, however, a mechanism causing
activation of tyrosine kinases to phosphorylate TauT either is not present or is not
activated by cell swelling. Thus, swelling would have no effect on astrocytic TauT
localization or transport activity. Alternatively, astrocytic TauT may differ in sequence
and/or structure from neuronal TauT in a manner that precludes tyrosine kinase
phosphorylation. Thus, swelling also would not affect astrocytic TauT in this situation.
PKC in our model controls the intracellular pool of TauT and steady-state cycling
of TauT from this intracellular pool to or from the plasma membrane in both cell types.
Inhibition of PKC in neurons changes the balance of the steady-state cycling to favor
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insertion of TauT on the plasma membrane. Conversely, in astrocytes, activation of PKC
changes this balance to favor removal of TauT from the plasma membrane thus
decreasing TauT activity. Taken together, this model explains how cell swelling
differentially affects TauT activity, localization, and phosphorylation in astrocytes and
neurons.

Figure 40. Model of TauT Regulation in Hippocampal Neurons. Under normal
conditions, PKC regulates steady-state cycling of TauT to and from the plasma
membrane (A). Given a stimulus (e.g. TBI) which induces cell swelling, TK is activated
and phosphorylates TauT which then is internalized from the plasma membrane allowing
neurons to undergo RVD and maintain their normal cell volume (B). If TK is inhibited
during cell swelling, phosphorylation of TauT does not occur, TauT remains on the
plasma membrane, and cell volume recovery is reduced. Similarly, inhibition of PKC
during cell swelling tips the steady-state cycling of TauT toward insertion on the plasma
membrane (C). TK=tyrosine kinases, PKC=protein kinase C
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Figure 41. Model of TauT Regulation in Hippocampal Astrocytes. Under normal
conditions, PKC regulates steady-state cycling of TauT to and from the plasma
membrane (A). Given a stimulus (e.g. TBI) which induces cell swelling, TK is either
unable to be activated or cannot phosphorylate TauT. TauT remains on the plasma
membrane leading to accumulation of taurine with water osmotically following and
resulting in persistent cell swelling (B). Upon activation of PKC under normal conditions,
TauT is phosphorylated and steady-state cycling is tipped toward internalization of the
protein from the plasma membrane (C). TK=tyrosine kinases, PKC=protein kinase C

Internalization of TauT Allows Neurons to Regulate Their Cell Volume.
Internalization of the taurine transporter from the plasma membrane during cell swelling
may account for the reduction in functional TauT transport activity observed in swollen
neurons and could contribute to neuronal volume regulation. During osmotic brain edema
caused by systemic hypoosmotic exposure in rat cerebellum, there is a net efflux of
taurine from neurons and an accumulation of taurine by glia (Nagelhus, Lehmann et al.
1993). The result is that neurons are able to maintain their cell volume while glia swell.
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While taurine efflux increases when either cell type is swollen, the influx rate for taurine
in glia remains unchanged (Schousboe, Sanchez-Olea et al. 1991). However, Olson &
Martinho (Olson and Martinho 2006a; Olson and Martinho 2006b) reported that when
neurons were exposed to hypoosmotic conditions, taurine accumulation significantly
decreased and remained decreased for a period of at least 30 min.
Our results correlate with these studies and suggest that internalization of TauT
from the plasma membrane is the mechanism by which taurine accumulation is decreased
and neurons are able to maintain their cell volume following conditions that mimic
osmotic brain edema. Our data also support those of Schousboe et al. who found no
change in glial taurine uptake during conditions of cell swelling and of Sanchez-Olea et
al. who showed no effect of hypoosmotic swelling on taurine transport activity in
astroglia (Sanchez-Olea, Moran et al. 1991; Schousboe, Sanchez-Olea et al. 1991). In our
studies, astrocytic cell swelling did not affect subcellular localization of TauT. Given our
observations, one could hypothesize that in vivo in osmotically swollen rat hippocampus
a decrease in TauT activity coupled with its removal from the plasma membrane in
neurons plus astrocyte TauT remaining on the plasma membrane and with unchanged
transport activity would facilitate a net transfer of taurine from neurons to glia thus
contributing to neuronal volume regulation and astroglial swelling during osmotic brain
edema. These studies could be explored using immunochemical quantification of taurine
cellular localization in the hippocampus using the methods of Nagelhus et al. (1993).
While the TauT protein is found in the nuclear fraction following hypoosmotic
swelling in neuronal cell fractionation experiments, it is unlikely that the transporter is
internalized into the nucleus. A more plausible explanation is that the TauT protein is

120

internalized within endosomes or targeted to a distinct recycling compartment that is
closely associated with the endoplasmic reticulum surrounding the nucleus. Studies by
Muller et al. suggest this type of regulation occurs for the serotonin transporter (SERT)
as it is internalized by the protein SCAMP2 (Muller, Wiborg et al. 2006). SERT is
internalized from the plasma membrane into neither TfR-positive endosomes nor to the
golgi apparatus. However, SERT and SCAMP2 interact in flotillin-positive lipid rafts
which have been shown to be part of the clathrin-independent endocytic pathway in
mammalian cells (Muller, Wiborg et al. 2006). A similar mechanism of internalization
occurs for the norepinephrine transporter (NET) (Jayanthi, Samuvel et al. 2004). Jayanthi
et al. have shown that NET is internalized following activation of PKC in rat placental
trophoblasts (Jayanthi, Samuvel et al. 2004). Double negative mutants of dynamin could
not block this effect suggesting a clathrin-independent mechanism. However, blocking
caveolae/lipid raft-mediated internalization blocked the PKC-mediated effect (Jayanthi,
Samuvel et al. 2004).
Since these SLC6 proteins are regulated through these translocation mechanisms,
it is likely that TauT is internalized in a similar manner. While our immunoprecipitation
data suggested TauT was co-localized with the cytoskeletal protein, actin, future studies
should aim to explore TauT co-localization with markers of various intracellular
structures (e.g. TfR-positive endosomes, trans-golgi network, lipid rafts, etc.). Sucrose
density gradient centrifugation could also be used to assess TauT localization in lipid
rafts to further elucidate the mechanism of TauT internalization from the plasma
membrane under conditions of cell swelling. Here we have provided a first assessment of
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how differential regulation of TauT localization in neurons and glia may combine to
allow maintenance of neuronal cell volume while glia swell during osmotic brain edema.

Tyrosine Kinases Regulate TauT Localization in Neurons. It was previously shown
by Olson and Martinho that the decrease in TauT functional activity with hypoosmotic
swelling can be reversed by inhibition of tyrosine kinases with 100 µM genistein (Olson
and Martinho 2006a; Olson and Martinho 2006b). In that study TauT activity decreased
with hypoosmotic swelling in neurons independent of changes in extracellular sodium
and chloride concentrations. Additionally the decrease in maximal transport activity was
not due to a decreased energy state of the cell since ATP contents did not change in
comparison to cells in isoosmotic conditions (see Figure 7). The downregulation of
taurine transport rate was, however, blocked when tyrosine kinases were inhibited with
genistein. Consistent with this effect of tyrosine kinases on TauT activity, orthovanadate,
a protein tyrosine phosphatase inhibitor, decreased the rate of taurine transport under
isoosmotic conditions (Olson and Martinho 2006a; Olson and Martinho 2006b).
Tyrosine kinases regulate the activity of other membrane transporters as well (e.g.
the sodium/myo-inositol cotransporter (SMIT) in MDCK cells) (Atta, Dahl et al. 1999).
Inhibition of tyrosine kinases under conditions of hypertonicity in these cells increases
SMIT activity and SMIT mRNA abundance (Atta, Dahl et al. 1999). In a separate study,
Whitworth and Quick (Whitworth and Quick 2001) demonstrated that tyrosine
phosphorylation is required for up-regulation of gamma-aminobutyric acid transporter
(GAT1) expression on the plasma membrane in Chinese hamster ovary cells (Whitworth
and Quick 2001). In correlation with these studies, our results suggest that a tyrosine
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kinase pathway was responsible for phosphorylation of TauT under conditions of cell
swelling and that this signal caused internalization of TauT from the plasma membrane
resulting in decreased TauT functional activity. This would allow neurons to regulate
their cell volume during osmotic brain edema.

PKC Regulation of TauT in Neurons. In contrast with previous studies by Han et al.
who found a specific serine residue, phosphorylated by PKC, on the kidney TauT to be a
critical regulator of the transporter, neuronal TauT is unaffected by activation of PKC in
our studies. Similarly, Tchoumkeu-Nzouessa and Rebel observed no effect of PKC on
neuronal taurine accumulation (Tchoumkeu-Nzouessa and Rebel 1996). However, in our
studies PKC inhibition blocked the decrease in neuronal membrane TauT with cell
swelling which is in contrast to these studies. Because this effect was assessed using only
cell fractionation and not cell surface biotinylation, it could be that the increase in
neuronal membrane TauT seen in this case is a combination of plasma membrane and
other intracellular membranes. It may also be that PKC is in fact a regulator of TauT in
neurons. Further studies should focus specifically on plasma membrane TauT in response
to PKC inhibition to clarify this result.

PKC Regulates TauT Localization in Astrocytes. In our studies PKC activation caused
phosphorylation and internalization of TauT in astrocytes. Previous studies in retina,
kidney, and astrocytes have reported decreased carrier-mediated taurine accumulation
upon PKC activation (Loo, Hirsch et al. 1996; Tchoumkeu-Nzouessa and Rebel 1996;
Tchoumkeu-Nzouessa and Rebel 1996; Han, Budreau et al. 1999). Others have suggested
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that control of TauT may be mediated by different biochemical pathways depending on
the cell/tissue type being studied. When activated, PKC causes internalization of
astrocytic TauT from the plasma membrane thus decreasing functional TauT activity and
net taurine accumulation.
PKC regulates other SLC6 transporters as well. For example, protein kinase C
(PKC) downregulates the serotonin transporter by causing a redistribution of the protein
from the plasma membrane to intracellular compartments (Muller, Wiborg et al. 2006).
This mechanism of redistribution is thought to be a common regulatory mechanism for
protein transporters and is consistent with data showing that PKC-mediated transport
inhibition is associated with a decrease in Vmax with no change in Km (Masson, Sagne et
al. 1999; Chen, Reith et al. 2004). Protein kinase C and protein kinase A (PKA)
consensus phosphorylation sites in the cytosolic domains of organic osmolyte
transporters signify regulation by second messenger systems that could alter the affinity
of transporters for their substrate or change transporter numbers leading to changes in
transport rate (Clark and Amara 1993). In oocytes injected with Madin-Darby Canine
kidney (MDCK) cell TauT, PKC activation leads to a decrease in taurine transport and
PKC inhibition leads to an increase in taurine transport (Han and Chesney 2006). Ser-322
was confirmed to be the critical site for PKC phosphorylation in these cells (Han and
Chesney 2006; Han, Patters et al. 2006). Other studies of TauT in cortical neurons,
astrocytes, kidney cells, placental choriocarcinoma cells, and macrophages have
implicated PKC, PPI-3, cAMP, NO, TNFα, and LPS as potential intracellular signaling
molecules which could modify taurine accumulation rates (Kulanthaivel, Cool et al.
1991; Kilberg, Stevens et al. 1993; Han, Budreau et al. 1999; Olson and Martinho
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2006b). Thus PKC cannot be eliminated as a potential regulator of TauT in either neurons
or astrocytes.

Potential TauT Phosphorylation Sites. Although transporters have been shown to be
regulated by a variety of protein kinases (e.g. PKC, PKA, TK, etc.), direct molecular
modifications (e.g. phosphorylation) have not been evaluated for neuronal or astrocytic
TauT (Kilberg, Stevens et al. 1993; McGivan and Pastor-Anglada 1994; Chen, Reith et
al. 2004). These studies are the first examination, to our knowledge, of brain cell-specific
post-translational modifications (PTM) of the taurine transporter.
The TauT protein has several potential sites for phosphorylation on cytoplasmic
loops (Smith, Borden et al. 1992). Specifically, the kidney cell taurine transporter
(pNCT) has putative PKC phosphorylation sites at Ser-45, Thr-175, Ser-215, Thr-242,
Ser-322, and Thr-581 (Han, Budreau et al. 1999). Based on sequence homology, these
putative phosphorylation sites are likely similar between pNCT and rat brain TauT. Using
the NetPhos 2.0 server, neural network predictions for serine, threonine, and tyrosine
phosphorylation sites were made for the rat brain TauT sequence (Blom, Gammeltoft et
al. 1999). These putative sites were compared with the putative phosphorylation sites for
pNCT reported by Han et al. (Han, Budreau et al. 1999). Residues that fell within
predicted transmembrane domains or on extracellular loops of the rat brain TauT
sequence were eliminated as potential phosphorylation sites since signaling was likely
intracellular. This resulted in a total of 5 putative serine, 5 putative threonine, and 1
putative tyrosine phosphorylation site including Ser-21, Ser-25, Thr-28, Ser-45, Ser-46,
Thr-242, Tyr-320, Ser-322, Thr-581, Thr-596, and Thr-603. Specific peptide fragments
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containing these residues following a hypothetical tryptic digest were manually predicted
and correlated to the ExPASy proteomics server of the Swiss Institute of Bioinformatics
(SIB) Peptide Cutter tool for the prediction of potential cleavage sites by trypsin in the rat
brain TauT sequence (Figure 42 and Table 7) (Gasteiger, Gattiker et al. 2003; Artimo,
Jonnalagedda et al. 2012). Serine-21, 25, 45, and 46 and Thr-28 are part of the
intracellular N-terminus of TauT. Threonine-242 is on a small intracellular loop located
between transmembrane domains (TMD) 4 and 5. Tyrosine-320 and Ser-322 are located
on an intracellular loop between TMDs 6 and 7. Threonine-581, 596, and 603 are located
on the C-terminal tail. Of particular interest are the Tyr-320 and Ser-322 sites on the 3rd
intracellular loop. These residues are separated by a single amino acid and thus allow the
potential for access to both tyrosine kinases and PKC at a similar location on TauT.
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Figure 42. Theoretical Tryptic Digest of TauT. Predicted peptide fragments from an
in-gel tryptic digest of TauT are shown on the left. The highlighted fragment represents
the peptide containing Ser-322 which is critical for the regulation of TauT in MadinDarby Canine Kidney (MDCK) cells.
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Table 7. Potential Phosphorylation Sites within Predicted Tryptic Fragments of
TauT. Predicted tryptic digestion peptide fragments from rat brain TauT containing
amino acids which are potential targets for phosphorylation by tyrosine kinases or protein
kinase C are shown. Phosphorylation sites are indicated in bold face type.

Evaluation of Sequence Differences in Neuronal and Astrocytic TauT. Although rat
brain TauT shares >91% sequence identity with taurine transporters cloned from mouse
retina, human placenta, MDCK cells, and bovine aortic endothelium, TauT has not been
sequenced in individual cell types in the brain (i.e. neurons and astrocytes) (Qian,
Vinnakota et al. 2000). Because of the possibility of regulation of TauT by different
signaling pathways in these cells, it is possible that an unknown sequence difference
exists in neurons and astrocytes. We aimed to clarify this possible sequence difference in
neuronal and astrocytic TauT using mass spectrometry. We first used whole cell lysate
and 1D SDS-PAGE followed by an in-gel tryptic digest and MALDI-TOF/TOF MS of
TauT bands (identified by an identical immunoblot) to sequence TauT. This produced
results which suggested that many proteins were present in the ~75 kDa protein band, but
identified none that clearly represented TauT. It was apparent that we needed to further
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separate TauT from these other proteins in order to decrease the noise and increase the
chances of obtaining a relevant peptide sequence corresponding to our protein of interest.
Thus, we used 2D gel electrophoresis to separate the proteins in our sample by both
molecular weight and isoelectric point.
Liu et al. reports an acidic pI for TauT of 5.98 while the SequenceEditor software
used at the WSU-PAL laboratory estimates TauT pI to be 7.1 (Liu, Lopez-Corcuera et al.
1992). It was because of this discrepancy and also because various molecular weights
have been reported for TauT in different preparations (Han, Budreau et al. 1996; Poulsen,
Litman et al. 2002; Xu, Wagenfeld et al. 2003; Iruloh, D'Souza et al. 2007), that we
turned to a comprehensive analysis of all proteins in primary hippocampal neurons,
1321N1 cells (astrocytoma cell line), C6 cells (glioma cell line), and primary
hippocampal astrocytes. Despite a considerable effort and the identification of many
proteins in these cell lysates, we were unable to identify the TauT protein in either neuron
or astrocyte cell lysate. It may be that despite the use of 1D and 2D gel electrophoresis,
the TauT protein was insufficiently isolated or in a concentration too low to be resolved
by the mass spectrometer. Increasing the number of cell cultures that were used for each
experiment did not improve this sensitivity sufficiently. In addition, the multiple
processing steps necessary for SDS-PAGE and mass spectrometric analysis may have
decreased the overall yield of TauT in the final samples. Although TauT has eluded us
here, it is clear that our methods were optimized for the identification of multiple proteins
in raw cell lysate and immunoprecipitated cell lysates using both 1-dimensional and 2dimensional gel electrophoresis. Further optimization of our protocols for processing
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membrane proteins is needed to successfully identify TauT and sequence the protein for
comparison in the different cell types.

Cytoskeletal Regulation of Cell Volume. An interesting discovery in these studies was
the presence of a 50 kDa band immunoreactive to the TauT antibody in biotinylated
preparations and in immunoprecipitates of TauT from raw cell lysate. Mass spectrometric
analysis unequivocally identified the 50 kDa band as actin in both neurons and astrocytes.
In the studies presented here, actin immunoprecipitated with the taurine transporter under
both isoosmotic and hypoosmotic conditions in neurons and astrocytes. Thus, a direct
connection between TauT and the actin cytoskeleton may provide a mechanism by which
the transporter is trafficked to or from the plasma membrane.
The existence of a membrane-cytoskeleton in cells has suggested an involvement
of microfilaments in monitoring cell shape associated with cell volume changes and also
in regulating various membrane transport proteins (Mills, Schwiebert et al. 1994; Henson
1999). This is evidenced in Ehrlich ascites tumor cells (EATC) where as early as 1 min
after osmotic challenge there was a change in both cortical content of F-actin and net Factin content for the whole cell (Pedersen, Mills et al. 1999; Pedersen, Hoffmann et al.
2001). In general, osmotic swelling was associated with a decrease in actin
polymerization and a net decrease in F-actin content while osmotic shrinkage promoted
actin polymerization and a net increase in F-actin content (Pedersen, Mills et al. 1999;
Pedersen, Hoffmann et al. 2001). Accordingly, Ziyadeh et al. found that hypoosmotic
swelling of shark rectal glands causes depolymerization of F-actin and efflux of organic
osmolytes including taurine (Ziyadeh, Mills et al. 1992). F-actin changes correlated with
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taurine efflux kinetics and it was projected that transient loss of F-actin organization in
these cells allowed selective efflux of organic osmolytes thus allowing RVD. Similarly,
Moran et al. showed reorganization of F-actin structure to a diffuse actin network in the
cell body of cultured rat cerebellar astrocytes following hypoosmotic exposure (Moran,
Sabanero et al. 1996). In human promyelocytic leukemic (HL-60) cells, cytoskeletalassociated actin decreased from 22% (isotonic conditions) to ~12% of total cellular actin
upon cell swelling but this did not seem to correlate closely with changes in cell volume
regulation (i.e. RVD) (Hallows, Packman et al. 1991; Hallows, Law et al. 1996).
Additional evidence linking the actin cytoskeleton with cell volume regulation comes
from studies using cytochalasins to disrupt actin organization. In general these actin
inhibitors hinder a cell’s ability to undergo RVI or RVD (Henson 1999).
Additional evidence for a connection between TauT and the membrane
cytoskeleton comes from studies showing that several plasma membrane transporters
involved in cell volume regulation are structurally linked to the cytoskeleton and may be
functionally regulated by changes in the organization of F-actin (Basham, Chabrerie et al.
2001; Doherty and McMahon 2008). Transporters involved in RVD and known to be
linked to actin cytoskeleton include channels and transporters of organic osmolytes, K +
channels, Cl- channels, and HCO3-/Cl- channels (Henson 1999). Transporters involved in
RVI and linked to the actin cytoskeleton include the Na+/H+ exchanger, NKCC, and
HCO3-/Cl- channels (Henson 1999). The nACh receptor channel at the neuromuscular
junction and the Cl-/HCO3- exchanger in renal epithelia are linked to the actin
cytoskeleton and these cytoskeletal associations are suggested to regulate the opening and
closing of these ion channels (Mills, Schwiebert et al. 1994). In this way, the
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reorganization of the actin cytoskeleton during osmotic perturbations may be responsible
for modulation of ion and osmolyte transport. In fact, Schwiebert et al. described a
requirement of F-actin disruption for osmotic swelling-induced activation of Cl- channels
and regulatory volume decrease in RCCT-28A cells (Schwiebert, Mills et al. 1994). In
HT-3 cells (HPV-negative cervical cancer cell line) actin disruption increased Clconductance in isotonic conditions and even more so in hypoosmotic conditions (Shen,
Chou et al. 1999). While there has been a heavy focus on the efflux of ions and organic
osmolytes for the control of cell volume and the cytoskeletal organization affecting these
pathways, it is unclear how cell swelling and alterations in the actin cytoskeleton may
affect the membrane transport pathways responsible for the accumulation of organic
osmolytes. Our studies suggest a possible interaction between actin and TauT which,
when activated by cell swelling, would provide a mechanisms for transporter
internalization.
Another component to this potential interaction is the association between the
actin cytoskeleton and various signaling molecules which are known to act on transport
proteins. Many effectors of volume-regulated transport proteins are associated with the
cytoskeleton including small G-proteins, phospholipases, lipid kinases, PtdIns(4,5)P 2, etc
(Pedersen, Hoffmann et al. 2001). Members of the signaling pathways interact with the
cytoskeleton within minutes of cellular volume perturbation (Pedersen, Hoffmann et al.
2001). For example, upon osmotic swelling or shrinkage, MAPK subfamilies (ERK1/2,
JNK, and p38) modulate F-actin organization (Pedersen, Hoffmann et al. 2001). Further,
a change in actin polymerization may alter its interaction with membrane transporters
which could upregulate or downregulate transporter activity (Mills, Schwiebert et al.
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1994). NKCC1 activation in response to cell swelling is inhibited by stabilization of Factin while shrinkage-induced NKCC1 activation is inhibited by F-actin
depolymerization (Hallows, Law et al. 1996; Pedersen, Hoffmann et al. 2001).
The possibility of an interaction between actin and TauT presented in these
studies opens the door for many new experimental approaches to explore the taurine
transporter’s role in brain cell volume regulation. Does a TauT and actin interaction
provide a mechanism for transporter cycling to and from the plasma membrane in
response to cell swelling and/or cell signaling pathways? Is actin the mediator between
cell swelling and the activation of kinase signaling pathways which act on TauT? These
questions only begin to explore the possibilities for further research in cell volume
regulation.

Conclusions. The taurine transporter is differentially regulated by osmotic swelling and
kinase signaling pathways in rat hippocampal neurons and astrocytes. While neuronal
TauT is phosphorylated by tyrosine kinases and internalized in response to cell swelling,
astrocytic TauT phosphorylation and localization is unaffected. Astrocytic TauT,
however, is regulated by a PKC-mediated signaling pathway. Our model suggests that the
primary mediator of taurine transport regulation in neurons is a tyrosine kinase signaling
pathway whereas the primary mediator of taurine transport regulation in astrocytes is a
PKC-mediated signaling pathway. This differential signaling mechanism causes TauT to
be internalized in neurons during cell swelling while astrocytic TauT remains unaffected
on the plasma membrane. This cell-specific response to swelling also would facilitate net
transfer of taurine from neurons to astrocytes (Nagelhus, Lehmann et al. 1993) allowing
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neurons to regulate their cell volume while astrocytes swell during osmotic brain edema.
Furthermore, this may be a physiologically protective mechanism which affords neurons
protection from altered function resulting from cell volume changes. Alternatively, this
differential regulation could create the pathology and thereby the symptomology
associated with excessive astroglial swelling observed in osmotic brain edema.
Understanding how the taurine transporter, signaling pathways, and the cytoskeleton are
interrelated is relevant for understanding the overall mechanisms of brain cell volume
regulation. Further studies of these phenomena and cellular regulatory mechanisms will
move research toward the discovery of pharmacological targets for the treatment and
prevention of uncontrollable brain cell swelling.
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VII. FUTURE DIRECTIONS
Although these studies have addressed several questions about taurine transport in
brain cells that were previously unanswered, much work remains to be completed to fully
understand the regulation of TauT in both neurons and astrocytes. A major step forward
in the understanding of TauT regulation would be to clone TauT from both neurons and
astrocytes followed by DNA sequence analysis to compare and characterize the protein in
each cell type. Sequence alignment of neuronal and astrocytic TauT as well as TauT
cloned from other cells and tissues (e.g. mouse retina, human placenta, MDCK cells, etc.)
holds the potential for identification of sequence differences in these proteins.
Uncovering amino acid sites of non-homology may explain the differential regulation
seen in the two cell types studied here. Identification of such sites could lead to
experiments where amino acid residues are altered to further assess the site-specific
regulation of TauT. Further optimization of our mass spectrometry protocols for the
processing of membrane proteins is also needed to successfully identify TauT posttranslational modifications in these cells. Additionally, inhibitors that block proteases
which are not traditionally inhibited in protease inhibitor cocktails should be added to cell
lysis solutions, especially in astrocytes, to assess whether cleavage sites not present in
neurons exist in these cells. At the very least, it will be necessary to generate custom
TauT antibodies specifically immunoreactive to the protein in specific tissue/cell lines of
interest in order to provide more accurate analysis by western blots,
immunocytochemistry and immunoprecipitation.
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Future experiments also should focus on further addressing the PKC and tyrosine
kinase pathways involved in TauT regulation in neurons and astrocytes. It would be
interesting to examine if the effect of activation of PKC in astrocytes remains in the
presence of various PKC subtype inhibitors. Additionally, studies should clarify whether
the internalization of TauT is truly reversed by inhibition of PKC with cell swelling in
neurons or whether this effect was a result of our assay measuring TauT that is not
specifically directed to the plasma membrane. It will also be relevant to study the
localization of TauT following recovery of the cells in isoosmotic conditions. Does TauT
remain in intracellular compartments following recovery from cell swelling or is it
recycled back to the plasma membrane? Studies should aim to explore TauT colocalization with markers of various intracellular structures (e.g. TfR-positive endosomes,
trans-golgi network, lipid rafts, etc.). Also, given an appropriate antibody specific to
neuronal and astrocytic TauT, confocal microscopy and/or live cell imaging will be
useful tools to demonstrate cycling of TauT to and from the plasma membrane under cell
swelling conditions. This will further elucidate the mechanism of TauT internalization
from the plasma membrane and provide information on the recycling and/or degradation
of TauT following osmotic insults.
Given the interesting observations of Nagelhus et al. (Nagelhus, Lehmann et al.
1993), experiments which aim to assess taurine transfer from neurons directly to
astrocytes under conditions of cell swelling are necessary. Hippocampal slices could be
treated with radiolabeled taurine under normal conditions and conditions of cell swelling.
Autoradiography could then be used to quantify cell-specific taurine accumulation. Rates
of taurine accumulation in neurons and astrocytes in normal conditions would be
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compared with the rates measured in hypoosmotic conditions and these data correlated
with the relative intensity of taurine-like immunostaining. This would provide insight on
the proposal that differential signaling and regulation of TauT facilitates net movement of
taurine from hippocampal neurons to astrocytes during hypoosmotic exposure.
Finally, future studies should aim to characterize the interaction between TauT
and the actin cytoskeleton. A connection between these two proteins would provide a
mechanism for transporter cycling to and from the plasma membrane in response to cell
swelling and/or cell signaling pathways. It may also elucidate the identity of the mediator
between cell swelling and the activation of kinase signaling pathways which act on TauT.
Taken together, our studies have not only advanced the characterization of the differential
regulation of TauT in neurons and astrocytes, but have also opened the door for a variety
of new studies to explore the relationship of osmotic responses in these two cell types.
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VIII. APPENDIX A
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Figure 43. MALDI TOF/TOF Identification of Heat Shock Protein in Neurons. Mass
spectrum for a protein sample from the immunoprecipitation of neuronal cell lysate (A).
Fragmentation of parent peaks 1253 (B) and 1981 (C) revealed amino acid sequences
with significant homology to heat shock cognate protein 70 kDa (D, E). Protein scores
were derived from ion scores (-10*Log(P), where P is the probability that the observed
match is a random event). Individual ion scores > 49 indicated identity or extensive
homology (p < 0.05).
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Figure 44. MALDI TOF/TOF Identification of a Serum Albumin Precursor Protein
in Neurons. Mass spectrum for a protein sample from the immunoprecipitation of
neuronal cell lysate (A). Fragmentation of parent peaks 927 (B), 1479 (C), and 1567 (D)
revealed amino acid sequences with significant homology to a serum albumin precursor
(E, F). Protein scores were derived from ion scores (-10*Log(P), where P is the
probability that the observed match is a random event). Individual ion scores > 38
indicated identity or extensive homology (p < 0.05).
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Figure 45. MALDI TOF/TOF Identification of Tubulin in Neurons. Mass spectrum
for a protein sample from the immunoprecipitation of neuronal cell lysate (A).
Fragmentation of parent peaks 1085 (B), 1457 (C), 1701 (D), and 1718 (E) revealed
amino acid sequences with significant homology to a tubulin (F, G). Protein scores were
derived from ion scores (-10*Log(P), where P is the probability that the observed match
is a random event). Individual ion scores > 39 indicated identity or extensive homology
(p < 0.05).
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Figure 46. MALDI TOF/TOF Identification of Actin in Neurons. Mass spectrum for a
protein sample from the immunoprecipitation of neuronal cell lysate (A). Fragmentation
of parent peaks 976 (B), 1132 (C), 1515 (D), and 1790 (E) revealed amino acid
sequences with significant homology to actin (D). Protein scores were derived from ion
scores (-10*Log(P), where P is the probability that the observed match is a random
event). Individual ion scores > 55 indicated identity or extensive homology (p < 0.05).

162

163

164

165

Figure 47. MALDI TOF/TOF Identification of Large Tegument Protein in Neurons.
Mass spectrum for a protein sample from the immunoprecipitation of neuronal cell lysate
(A). Fragmentation of parent peak 1189 (B) revealed an amino acid sequence with
significant homology to a large tegument protein (C). Protein scores were derived from
ion scores (-10*Log(P), where P is the probability that the observed match is a random
event). Individual ion scores > 40 indicated identity or extensive homology (p < 0.05).
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Figure 48. MALDI TOF/TOF Identification of Keratin in Neurons. Mass spectrum
for a protein sample from the immunoprecipitation of neuronal cell lysate (A).
Fragmentation of parent peaks 973 (B) and 1179 (C) revealed amino acid sequences with
significant homology to keratin (D). Protein scores were derived from ion scores (10*Log(P), where P is the probability that the observed match is a random event).
Individual ion scores > 40 indicated identity or extensive homology (p < 0.05).
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Figure 49. MALDI TOF/TOF Identification of Keratin in Neurons. Mass spectrum
for a protein sample from the immunoprecipitation of neuronal cell lysate (A).
Fragmentation of parent peaks 973 (B), 1179 (C), and 1475 (D) revealed amino acid
sequences with significant homology to keratin (E). Protein scores were derived from ion
scores (-10*Log(P), where P is the probability that the observed match is a random
event). Individual ion scores > 40 indicated identity or extensive homology (p < 0.05).
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Figure 50. MALDI TOF/TOF Identification of Actin in Neurons. Mass spectrum for a
protein sample from the immunoprecipitation of neuronal cell lysate (A). Fragmentation
of parent peaks 976 (B), 1132 (C), 1516 (D), and 1790 (E) revealed amino acid
sequences with significant homology to a actin (F, G). Protein scores were derived from
ion scores (-10*Log(P), where P is the probability that the observed match is a random
event). Individual ion scores > 39 indicated identity or extensive homology (p < 0.05).
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Figure 51. MALDI TOF/TOF Identification of Keratin in Neurons. Mass spectrum
for a protein sample from the 2D SDS-PAGE of neuronal cell lysate (A). Fragmentation
of parent peaks 1179 (B), 1277 (C), and 1717 (D) revealed amino acid sequences with
significant homology to keratin (E, F). Protein scores were derived from ion scores (10*Log(P), where P is the probability that the observed match is a random event).
Individual ion scores > 50 indicated identity or extensive homology (p < 0.05).
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Figure 52. MALDI TOF/TOF Identification of a Serum Albumin Precursor in
Neurons. Mass spectrum for a protein sample from the 2D SDS-PAGE of neuronal cell
lysate (A). Fragmentation of parent peak 927 (B), 1439 (C), 1479 (D), 1567 (E), and
1639 (F) revealed amino acid sequences with significant homology to a serum albumin
precursor (G). Protein scores were derived from ion scores (-10*Log(P), where P is the
probability that the observed match is a random event). Individual ion scores > 40
indicated identity or extensive homology (p < 0.05).
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Figure 53. MALDI TOF/TOF Identification of Tubulin in Neurons. Mass spectrum
for a protein sample from the 2D SDS-PAGE of neuronal cell lysate (A). Fragmentation
of parent peaks 1028 (B), 1053 (C), 1077 (D), 1130 (E), 1159 (F), and 1636 (G) revealed
amino acid sequences with significant homology to a tubulin (H). Protein scores were
derived from ion scores (-10*Log(P), where P is the probability that the observed match
is a random event). Individual ion scores > 40 indicated identity or extensive homology
(p < 0.05).
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Figure 54. MALDI TOF/TOF Identification of Calmodulin in Neurons. Mass
spectrum for a protein sample from the 2D SDS-PAGE of neuronal cell lysate (A).
Fragmentation of parent peak 1563 (B) revealed an amino acid sequence with significant
homology to calmodulin (C). Protein scores were derived from ion scores (-10*Log(P),
where P is the probability that the observed match is a random event). Individual ion
scores > 51 indicated identity or extensive homology (p < 0.05).
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Figure 55. MALDI TOF/TOF Identification of Stathmin in Neurons. Mass spectrum
for a protein sample from the 2D SDS-PAGE of neuronal cell lysate (A). Fragmentation
of parent peaks 945 (B), and 1388 (C) revealed amino acid sequences with significant
homology to stathmin (D). Protein scores were derived from ion scores (-10*Log(P),
where P is the probability that the observed match is a random event). Individual ion
scores > 40 indicated identity or extensive homology (p < 0.05).
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Figure 56. MALDI TOF/TOF Identification of Stathmin in Neurons. Mass spectrum
for a protein sample from the 2D SDS-PAGE of neuronal cell lysate (A). Fragmentation
of parent peak 1388 (B) revealed an amino acid sequence with significant homology to
stathmin (C). Protein scores were derived from ion scores (-10*Log(P), where P is the
probability that the observed match is a random event). Individual ion scores > 40
indicated identity or extensive homology (p < 0.05).
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Figure 57. MALDI TOF/TOF Identification of Bradykinin Inhibitor Peptide in
Astrocytes. Mass spectrum for a protein sample from the immunoprecipitation of
astrocyte cell lysate (A). Fragmentation of parent peak 1063 (B) revealed an amino acid
sequence with significant homology to bradykinin inhibitor peptide (C). Protein scores
were derived from ion scores (-10*Log(P), where P is the probability that the observed
match is a random event). Individual ion scores > 40 indicated identity or extensive
homology (p < 0.05).
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Figure 58. MALDI TOF/TOF Identification of Serum Albumin in Astrocytes. Mass
spectrum for a protein sample from the immunoprecipitation of astrocyte cell lysate (A).
Fragmentation of parent peaks 927 (B), 1479 (C), and 1567 (D) revealed amino acid
sequences with significant homology to serum albumin (E, F). Protein scores were
derived from ion scores (-10*Log(P), where P is the probability that the observed match
is a random event). Individual ion scores > 40 indicated identity or extensive homology
(p < 0.05).
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Figure 59. MALDI TOF/TOF Identification of Vimentin in Astrocytes. Mass
spectrum for a protein sample from the immunoprecipitation of astrocyte cell lysate (A).
Fragmentation of parent peaks 1093 (B), 1115 (C), 1296 (D), 1444 (E), and 1570 (F)
revealed amino acid sequences with significant homology to vimentin (G, H). Protein
scores were derived from ion scores (-10*Log(P), where P is the probability that the
observed match is a random event). Individual ion scores > 40 indicated identity or
extensive homology (p < 0.05).
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Figure 60. MALDI TOF/TOF Identification of Tubulin in Astrocytes. Mass spectrum
for a protein sample from the immunoprecipitation of astrocyte cell lysate (A).
Fragmentation of parent peak 1701 (B) revealed an amino acid sequence with significant
homology to tubulin (C, D). Protein scores were derived from ion scores (-10*Log(P),
where P is the probability that the observed match is a random event). Individual ion
scores > 40 indicated identity or extensive homology (p < 0.05).
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Figure 61. MALDI TOF/TOF Identification of Heat Shock Protein Beta-1 in
Astrocytes. Mass spectrum for a protein sample from the immunoprecipitation of
astrocyte cell lysate (A). Fragmentation of parent peak 1149 (B) revealed an amino acid
sequence with significant homology to heat shock protein beta-1 (C, D). Protein scores
were derived from ion scores (-10*Log(P), where P is the probability that the observed
match is a random event). Individual ion scores > 40 indicated identity or extensive
homology (p < 0.05).

245

246

247

248

249

Figure 62. MALDI TOF/TOF Identification of Keratin in Astrocytes. Mass spectrum
for a protein sample from the immunoprecipitation of astrocyte cell lysate (A).
Fragmentation of parent peaks 1493 (B), and 1707 (C) revealed amino acid sequences
with significant homology to keratin (E, D). Protein scores were derived from ion scores
(-10*Log(P), where P is the probability that the observed match is a random event).
Individual ion scores > 40 indicated identity or extensive homology (p < 0.05).
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Figure 63. MALDI TOF/TOF Identification of Keratin in Astrocytes. Mass spectrum
for a protein sample from the 2D SDS-PAGE of astrocyte cell lysate (A). Fragmentation
of parent peaks 1179 (B) and 1475 (C) revealed amino acid sequences with significant
homology to keratin (D, E). Protein scores were derived from ion scores (-10*Log(P),
where P is the probability that the observed match is a random event). Individual ion
scores > 40 indicated identity or extensive homology (p < 0.05).
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Figure 64. MALDI TOF/TOF Identification of Keratin in Astrocytes. Mass spectrum
for a protein sample from the immunoprecipitation of astrocyte cell lysate (A).
Fragmentation of parent peaks 1179 (B) and 1475 (C) revealed amino acid sequences
with significant homology to keratin (D, E). Protein scores were derived from ion scores
(-10*Log(P), where P is the probability that the observed match is a random event).
Individual ion scores > 48 indicated identity or extensive homology (p < 0.05).
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Figure 65. MALDI TOF/TOF Identification of Keratin in 1321N1 cells. Mass
spectrum for a protein sample from the 2D SDS-PAGE of 1321N1 cell lysate (A).
Fragmentation of parent peaks 1179 (B) and 1475 (C) revealed amino acid sequences
with significant homology to keratin (D, E). Protein scores were derived from ion scores
(-10*Log(P), where P is the probability that the observed match is a random event).
Individual ion scores > 40 indicate identity or extensive homology (p < 0.05).
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Figure 66. MALDI TOF/TOF Identification of Stathmin in 1321N1 cells. Mass
spectrum for a protein sample from the 2D SDS-PAGE of 1321N1 cell lysate (A).
Fragmentation of parent peak 1388 (B) revealed an amino acid sequence with significant
homology to stathmin (C, D). Protein scores were derived from ion scores (-10*Log(P),
where P is the probability that the observed match is a random event). Individual ion
scores > 39 indicate identity or extensive homology (p < 0.05).
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Figure 67. MALDI TOF/TOF Identification of Calmodulin in 1321N1 cells. Mass spectrum
for a protein sample from the 2D SDS-PAGE of 1321N1 cell lysate (A). Fragmentation of parent
peak 1265 (B) revealed an amino acid sequence with significant homology to calmodulin (C, D).
Protein scores were derived from ion scores (-10*Log(P), where P is the probability that the
observed match is a random event). Individual ion scores > 39 indicate identity or extensive
homology (p < 0.05).
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Figure 68. MALDI TOF/TOF Identification of Heterogeneous Nuclear
Ribonucleoproteins A2/B1 in 1321N1 Cells. Mass spectrum for a protein sample from
the 2D SDS-PAGE of 1321N1 cell lysate (A). Fragmentation of parent peaks 1013 (B),
1188 (C), and 1377 (D) revealed amino acid sequences with significant homology to
heterogeneous nuclear ribonucleoproteins A2/B1 (E, F). Protein scores were derived
from ion scores (-10*Log(P), where P is the probability that the observed match is a
random event). Individual ion scores > 40 indicated identity or extensive homology (p <
0.05)
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Figure 69. MALDI TOF/TOF Identification of Heat Shock Protein 90-Beta in C6
Cells. Mass spectrum for a protein sample from the 1D SDS-PAGE of C6 cell lysate (A).
Fragmentation of parent peaks 1194 (B), and 1513 (C), revealed amino acid sequences
with significant homology to heat shock protein 90-beta (D, E). Protein scores were
derived from ion scores (-10*Log(P), where P is the probability that the observed match
is a random event). Individual ion scores > 40 indicated identity or extensive homology
(p < 0.05).
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Figure 70. MALDI TOF/TOF Identification of Serum Albumin in C6 Cells. Mass
spectrum for a protein sample from the 1D SDS-PAGE of C6 cell lysate (A).
Fragmentation of parent peaks 913 (B), and 1455 (C), revealed amino acid sequences
with significant homology to a serum albumin precursor (D, E). Protein scores were
derived from ion scores (-10*Log(P), where P is the probability that the observed match
is a random event). Individual ion scores > 39 indicated identity or extensive homology
(p < 0.05).
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Figure 71. MALDI TOF/TOF Identification of Hypothetical Protein b1452 in E. coli.
Mass spectrum for a protein sample from the 2D SDS-PAGE of an E. coli control sample
(A). MS analysis revealed peptides with significant homology to hypothetical protein
b1452. (B, C). Protein scores were derived from ion scores (-10*Log(P), where P is the
probability that the observed match is a random event). Individual ion scores > 78
indicated identity or extensive homology (p < 0.05).
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Figure 72. MALDI TOF/TOF Identification of 60 kDa Chaperonin in E. coli. Mass
spectrum for a protein sample from the 2D SDS-PAGE of an E. coli control (A).
Fragmentation of parent peaks 1011 (B), 1454 (C), 1567 (D), and 1845 (E) revealed
amino acid sequences with significant homology to 60 kDa chaperonin (F, G). Protein
scores were derived from ion scores (-10*Log(P), where P is the probability that the
observed match is a random event). Individual ion scores > 38 indicated identity or
extensive homology (p < 0.05).
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Figure 73. MALDI TOF/TOF Identification of Elongation Factor Tu in E. coli. Mass
spectrum for a protein sample from the 2D SDS-PAGE of an E. coli control (A).
Fragmentation of parent peaks 1027 (B), 1233 (C), 1803 (D), and 1965 (E) revealed
amino acid sequences with significant homology to elongation factor Tu (F, G). Protein
scores were derived from ion scores (-10*Log(P), where P is the probability that the
observed match is a random event). Individual ion scores > 40 indicated identity or
extensive homology (p < 0.05).
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